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Mechanisms of telomerase inhibition by oxidized and therapeutic dNTPs 
Samantha Lynn Sanford, PhD 
University of Pittsburgh, 2020 
Telomeres cap chromosome ends and are essential for genome stability and human health, but they 
shorten in most human somatic cells with cell division due to the end replication problem. 
Telomerase a specialized reverse transcriptase that lengthens telomeres by adding GGTTAG 
repeats to chromosome ends and is upregulated in most human cancers to enable limitless 
proliferation. Here, we uncover two distinct mechanisms by which naturally occurring oxidized 
and therapeutic dNTP DNA precursors inhibit telomerase-mediated telomere elongation. We 
conducted a series of direct telomerase extension assays in the presence of modified dNTPs on 
various telomeric substrates. We provide direct evidence that telomerase can add the metabolized 
form of NRTIs, dideoxyadenosine 5’ triphosphate (ddITP) and 3’-azido-3’deoxythymidine 
triphosphate (AZT-TP), to the telomeric end, causing chain termination. In contrast, telomerase 
continues elongation after inserting oxidized 2-OH-dATP or the therapeutic 6-thioguanine 
metabolite, 6-thio-dGTP, but insertion disrupts translocation and inhibits further repeat addition. 
Kinetics reveal that telomerase poorly selects against 6-thio-dGTP, inserting with similar catalytic 
efficiency as dGTP. Furthermore, telomerase processivity factor POT1-TPP1 fails to restore 
processive elongation in the presence of inhibitory dNTPs. These findings reveal mechanisms for 
targeting telomerase with modified dNTPs in cancer therapy. 
v 
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1.1 Beginning of the end: A brief history of telomeres 
The field of telomere biology emerged in the 1930s from the work of two Nobel Prize 
winners, Hermann Muller and Barbara McClintock. They independently discovered telomeres first 
in fruit flies and then in corn. From the behavior of broken chromosomes, these scientists 
concluded that the natural ends of chromosomes were indistinguishable from induced DNA breaks 
and must be a specialized structure. Muller discovered that when fruit flies were irradiated with x-
rays, the majority of the genome would undergo breakage and fusion, but the very ends of each 
chromosome were resistant to breaking1. He hypothesized that the natural chromosome ends are 
somehow protected against the repair process, and named the protective structure the “telomere” 
1. McClintock independently discovered a similar phenomenon in irradiated maize chromosomes
2. She found that ruptured chromosomes formed dicentric chromosomes due to fusion of their ends
and that the damaged ends of chromosomes could be restored.  She concluded that one of the 
essential functions of telomeres was to protect chromosome ends from fusing with each other 
following  DNA double strand breaks 2.  
In hindsight, the next major advancement in telomere biology was in 1961, when the 
anatomist Leonard Hayflick demonstrated that fetal cells in culture divided only 40-60 times 
before halting division and becoming senescent, which is an irreversible arrest of cellular growth 
followed by serial passages of cultured human fibroblast cells 3. This concept was termed the 
Hayflick limit, which stated that aging of a cell parallels the overall physical aging of the human 
body 3. However, the molecular basis of the Hayflick limit wouldn’t be established for another 
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decade. The link between the Hayflick limit and telomeres was finally identified in the 1970s, 
when James Watson and Alexey Olovnikov independently proposed the “end replication problem” 
4,5. The end replication problem states that the unidirectionality of DNA polymerase would prevent 
the complete replication of a chromosome by lagging strand synthesis 4,5. However, it was 
Olovnikov that suggested the end replication problem would cause telomeres to shorten with each 
round of DNA replication, and that telomere shortening was the mechanism behind the Hayflick 
limit. As is often the case in science, the answer to one question raised another. If telomeres shorten 
with each cell division and eventually lead to replicative senescence, then how have organisms 
with linear chromosomes prevented the total erosion of their DNA over time? Olovnikov predicted 
that cells capable of indefinite replication must have a special DNA polymerase to maintain their 
telomeres. Olovnikov’s prediction sparked a race to find this protein that would take a decade of 
research to finally identify. 
In the early stage of her research career, Elizabeth Blackburn and her colleague Joseph Gall 
began to unravel the answer to the end replication problem. They found that the chromosome ends 
of Tetrahymena thermophila, a unicellular ciliate organism, had a six-base sequence TTGGGG 
which was repeated 20 to 70 times 6. Choosing Tetrahymena as an organism to complete these 
studies was a key factor to their initial success and following studies because it has thousands of 
chromosomes, which provide large quantities of telomeric material to analyze. By 1981, Backburn 
collaborated with Jack Szostak and found that telomeric function from Tetrahymena could be 
transformed into Saccharomyces cerevisiae 7. This work showed that some feature of the telomeric 
sequence confers function in multiple organisms. In 1985, Blackburn and her graduate student, 
Carol Greider, identified an enzyme capable of extending telomeric sequences 8. They identified a 
“terminal transferase” activity which they classified as a ribonucleoprotein with essential RNA 
3 
and protein components and termed it “telomerase” 8. The repetitive sequence of telomeric DNA 
combined with the lack of a template DNA strand led them to the conclusion that the RNA 
component of telomerase was complimentary to the telomeric repeat sequence, suggesting that it 
was acting as a template for telomeric repeat addition. In 2009, the Nobel Prize in Physiology or 
Medicine was awarded to Blackburn, Greider, and Szostak for their discovery of how 
chromosomes are protected by telomeres and the enzyme telomerase. These initial discoveries 
paved the way for thousands of studies published on telomeres and telomerase in a multitude of 
fields, including aging and cancer. 
1.2 Telomere structure and function 
Telomeres consist of repetitive noncoding DNA, which protect chromosomes from 
degradation and loss of essential genes. Mammalian telomeric DNA has a variable number of G-
rich, non-coding tandem repeats of a double stranded DNA sequence 5’-TTAGGG 3’/ 
5’CCCTAA-3’, followed by a 3’ G rich single stranded overhang. The 3’ overhang allows 
telomeric DNA to form a higher order structure wherein the 3’ single-stranded overhang folds 
back, loops around, and invades the double stranded telomeric DNA, forming a telomeric loop (T-
loop) that is stabilized by a displacement loop (D-loop). The T-loop prevents the ends of 
chromosomes from being recognized as double stranded breaks through the physical sequestering 
of chromosome ends away from DNA damage response machinery.  
Human telomeres are coated by a sequence specific protein complex called shelterin9. 
Shelterin interacts with both double and single stranded telomeric DNA and binds to the DNA in 
the nucleus 10. Human shelterin complex (Figure 1) consists of six distinct proteins: Protection of 
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telomeres 1(POT1), Ras-related protein 1 (RAP1), TERF1-interacting nuclear factor 2 (TIN2), 
tripeptidyl peptidase 1 (TPP1), and Telomeric repeat-binding factor 1 and 2 (TRF1 and TRF2) 9. 
TRF1 and TRF2 both bind to TIN2 which tethers the proteins together 10 11. TIN2 can also bind to 
TPP1, which in turn binds to POT1. RAP1 binds TRF2, which completes the six-subunit complex 
9.  
The DNA binding domains in the shelterin complex are well established. TRF1 and TRF2 
have Myb/SANT domains which bind to duplex telomeric DNA 12. The TRFH domain mediates 
the high affinity binding to DNA, which is dependent on TRF1 and TRF2 forming their own 
homodimers 13. The TRF1 and TRF2 homodimers create the double stranded 5’TAGGGTT-3’ 
recognition modules of shelterin. POT1 binds to single stranded telomeric DNA with two N-
terminal oligonucleotide binding (OB) folds. POT1 can bind to single stranded 5’-
TTAGGGTTAG-3’ sites at either the 3’ end or at an internal position such as the displaced strand 
of the D-loop 14. TPP1 also has an OB fold, but does not interact with DNA 15. Studies have shown 
that the shelterin complex binds as independent units to the DNA. In human and mouse cells, 
TRF1, TRF2, TIN2, and RAP1 are ten times more abundant than POT1 and TPP1, which suggests 
that the core of shelterin is a complex of the four must abundant subunits and a fraction of the 
complexes have TPP1 and POT1 16. TRF1 and TRF2 are abundant enough to cover all of the 
telomeric DNA in cells with short telomeres.  Cells with long telomeres (LT) are not fully coated 
with TRF2 but are fully protected 16.  Shelterin can bind to most double stranded TTAGGG repeats, 
and POT1/TPP1 are in ten-fold excess over its single stranded TTAGGG binding sites, which 
suggests that most of the telomeric DNA is associated with shelterin proteins 16.  
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1.2.1 End replication problem 
During each round of chromosome replication, telomeres shorten because of the 
incomplete replication of linear DNA by the conventional DNA polymerases. DNA polymerases 
synthesize DNA only in the 5’  3’ direction, and can only extend existing polynucleotide chains. 
Conventional DNA polymerases cannot synthesize DNA at the 5’ ends of a blunt ended DNA 
molecule. Therefore, the “end replication problem” causes incomplete lagging strand synthesis 
due to RNA primer removal 5. To circumvent this loss of telomeric DNA, shelterin functions to 
recruit a reverse transcriptase, known as telomerase, which can elongate the 3’ overhang by adding 
single stranded telomeric repeats 8.  
Figure 1. Shelterin complex. Consists of  six telomeric proteins: telomere repeat-binding factor 
1 and 2 (TRF1 and TRF2), repressor/activator protein 1 (RAP1), TRF1 interacting nuclear 
protein 2 (TIN2), TIN2-interacting protein 1 (TPP1) and protection of telomeres 1 (POT1). 




Telomerase is a large ribonucleoprotein complex, which processively synthesizes 
telomeric DNA repeats (5’-GGTTAG-3’ in humans) at the 3’ ends of linear chromosomes, 
restoring the DNA lost due to the end replication problem 17. Telomerase holoenzymes are 
heterogenous, but the minimally active complex consists of the catalytic protein component 
telomerase reverse transcriptase (TERT), and an integral telomerase RNA component (TR) and 
several accessory proteins (Figure 2) 18. TR acts as a template for the synthesis of telomeric DNA, 
and also aids in the localization, catalysis, and assembly of the telomerase holoenzyme (Figure 2). 
Figure 2. Telomerase at telomeres. Human telomerase consists of telomerase reverse transcriptase (hTERT), 
telomerase RNA component (hTR), and accessory proteins that are members of the H/ACA small nucleolar 
ribonucleoprotein family: dyskerin; NHP2 (non-histone protein 2); NOP10 (nucleolar protein 10); GAR1 
ribonucleoprotein. Created with Biorender. 
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1.3.1 Human telomerase RNA subunits  
The non-coding hTR (451 nucleotides in humans) is a subunit of telomerase and includes 
the template for DNA synthesis (Figure 3) 18.  hTR is involved at multiple stages of telomerase 
biogenesis and function. hTR has a template boundary element (TBE) which prevents run on 
reverse transcription past the end of the template 19. If the TBE is absent, telomerase can read 
through past the template to incorporate additional non-telomeric nucleotides 19. The pseudoknot 
and triple helix of hTR contribute to catalysis by orienting the primer-template duplex into the 
enzyme active site 20,21 . TR also contributes to the processivity of telomerase, allowing for 
multiple rounds of telomeric repeat addition after a single primer binding step 19,22. hTR can bind 
to the TERT subunit using the template-pseudoknot domain and the conserved region 4 and 5 
(CR4-CR5) domains 23. In addition to binding to TERT, hTR has important RNA structural and 
sequence elements which bind to various telomerase accessory proteins. The H/ACA small 
nucleolar RNAs (snoRNAs) box is located at the 3’ end of mammalian hTR, and is associated with 
the RNA binding proteins dyskerin, NHP2, nucleolar protein 10 (NOP 10), and GAR1 24. A Cajal 
box motif is also located in the 3’ domain of mammalian hTR and is bound to the beta transducin 
(WD repeat) domain protein known as telomerase Cajal Body protein 1 25. Localization of hTR in 
Cajal Bodies (regions in the nucleus enriched with proteins and RNAs involved in mRNA 
processing) is important, because this is where the RNP is packaged for delivery to telomeres 26. 




Figure 3. hTR secondary structure. The human telomerase RNA (hTR) contains three major structural and 
functional domains, the Pseudoknot/template domain,  the CR4/CR5 domain, and the H/ACA scaRNA 
domain. The hTR core and CR4/CR5 domains independently bind to hTERT. Created with Biorender.  
  
1.3.2 TERT subunit 
In addition to the RNA subunit described above, telomerase contains the telomerase reverse 
transciptase component, TERT. hTERT consists of 1132 amino acids and is highly conserved 
among species 28. hTERT contains four major domains: the TERT RNA binding domain (TRBD); 
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the telomerase essential N-terminal (TEN) domain; the reverse transciptase domain, and the C-
terminal extension domain (CTE) analogous to a polymerase thumb domain 29.  
Due to biophysical limitations such as low copy number and holoenzyme heterogeneity, 
there is a lack of atomic resolution structural information about human telomerase 30. Fortunately, 
the crystal structure of TERT from Tribolium casteneum, the red flour beetle, has provided a 
wealth of atomic resolution information to supplement the subnanometer cryo-EM structure of 
human telomerase 31. While tcTERT is highly homologous to hTERT, the RNA component of 
beetle telomerase has yet to be discovered. This has led to contention in the field of whether or not 
it is a true telomerase. Importantly, tcTERT contains the T-motif, which is an amino acid sequence 
preceding the RT motif that is conserved among TERT proteins, but not apparent in other reverse 
transcriptases 31. Because beetle telomerase has a T-motif, the beetle structure is believed to be 
either TERT or a very closely related protein. The beetle structure has revealed close contacts 
between the TRBD and the thumb subdomain of the RT domain, which results in a closed ring 
tertiary structure with a large cavity at is center, allowing for binding of the primer-template duplex 
32. A structure of the binary complex containing tcTERT bound to an RNA-DNA hairpin, which 
mimics the primer-template duplex, confirmed these contacts. The beetle structure shows that the 
fingers and palm domains of the RT interact with the backbone of the RNA arm of the hairpin in 
order to properly place the template in the active site. While the fingers and palm grasp the RNA 
template, the RT thumb binds the DNA primer of the hairpin.  
 
The TEN domain of TERT provides the anchor site which binds the telomeric DNA upstream from 
the primer-template duplex 33. For Tetrahymena thermophila TERT, the crystal structure of the 
TEN domain shows a fold with the groove of the surface which is important for DNA-primer 
binding and telomerase activity. The domain also has a DAT motif, which is involved in 
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telomerase recruitment 33. In addition to TR and TERT, there are also several accessory proteins 
which are involved in telomerase assembly, maturation, recruitment, and activation. hTERT is 
synthesized in the cytoplasm and associates with chaperones p23 and HSP90 34. Assembly of hTR 
and hTERT into active telomerase is aided by Reptin and Pontin, which belong to the AAA+ 
ATPase family 35. Telomerase is then recruited to Cajal bodies by interacting with TCAB, where 
it stays until it is recruited to telomeres 26.  
1.3.3 Telomerase recruitment to telomeres 
Since telomerase and its telomeric substrate have very low abundance (approximately 250 
telomerase molecules and 184 telomeres in a human cell during late S phase) 36, telomerase is 
actively recruited to telomeres instead of by simple diffusion. The shelterin component, TPP1, is 
responsible for telomerase recruitment to telomeres 37. TPP1 complexes with POT1 to stimulate 
telomerase repeat addition processivity (RAP) in vitro and is a processivity factor 15. The structure 
of TPP1 consists of an N-terminal OB-fold domain and is necessary for telomerase recruitment, a 
central domain that directly binds to POT1, and a C-terminal domain which associates with TIN2 
and thereby integrates POT1 and TPP1 into the shelterin complex 38,39. The TEL patch, which is a 
patch of amino acids in the OB-fold domain of TPP1, is essential for telomerase recruitment to 
telomeres in vivo and for stimulating telomerase RAP in vitro 40. Studies have shown that the TEL 
patch directly interacts with telomerase 41. Although TPP1 is essential for the recruitment of 
telomerase to mammalian telomeres, this interaction is regulated by the cell cycle because 
telomerase accumulates at telomeres only during the S phase 36.  
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1.3.4 Telomerase catalytic cycle  
The telomerase catalytic cycle begins with the RNA template 3’ end, which base pairs to 
the telomeric DNA substrate which primes DNA synthesis (Figure 4). After forming an RNA-
DNA duplex and addition of a dNTP, the telomerase active site closes to form an elongation 
conformation. Elongation continues until the template 5’ boundary is reached. When the template 
5’ region is in contact with the active site, the RNA template 5’ region is displaced and the RNA-
DNA hybrid is disrupted. Next, telomerase translocates along the newly synthesized telomeric 
repeat to allow the template region to be accessible for the next round of repeat synthesis. After 
template translocation, a short duplex RNA-DNA duplex is formed. If this duplex is captured into 
the TERT central cavity by conformational changes necessary for a functional active site, another 
round of repeat synthesis begins. Alternatively, if the active site cannot be restored, the substrate 
will dissociate and telomeric synthesis will not occur. The following section describes in more 
detail several components in the catalytic cycle, including nucleic acid handling, template 




1.3.4.1 Telomerase nucleic acid handling  
 
Telomerase catalyzes nucleotide addition to a primer 3’ hydroxyl group, which forms a 
product-template duplex similar to many DNA polymerases.  Telomerase and other polymerases 
also share a metal dependent chemistry of nucleotide addition 42. However, telomerase has several 
unique properties of nucleic acid handling, which other polymerases lack. Strict template copying 
boundaries within the telomerase RNA are necessary for accurate telomeric repeat synthesis. Also, 
telomerase can extend a DNA primer by processive addition of repeats. Repeat addition 
Figure 4. Telomerase catalytic cycle. Blue indicates the telomerase RNA template; black indicates DNA 
primer; red indicates newly added nucleotides; numbers represent the steps in the cycle. 
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processivity (RAP) allows for rearrangement of the product-template duplex without complete 
substrate dissociation of telomerase from DNA. The template dissociated ssDNA must maintain 
template independent interactions while the template repositions for base pairing of its 3’ end to 
prime the next telomeric repeat synthesis. The coordination of these events occurs as part of the 
full catalytic cycle of telomerase repeat synthesis 43.  
Telomerase is unique among other reverse transcriptases in its ability to use its internal 
RNA template for processive addition of multiple telomeric repeats, before dissociating from its 
DNA substrate 44. The number of repeats telomerase adds to the chromosome ends depends on 
both its catalytic activity, which is how fast it can catalyze nucleotide addition, and how many 
consecutive repeats it can add before dissociating. Repeat addition processivity (RAP) relies on 
the functional relationship of the specialized hTERT and RNA component. A single telomerase 
enzyme has the ability to add multiple repeats to the telomeric substrate processively.  This has 
been demonstrated by the synthesis of multiple repeats on an individual telomeric DNA molecule 
even when the telomeric molecule concentration is present in vast excess relative to the enzyme 
45. With a vast excess of primer, the probability of telomerase engaging with an already elongated 
primer compared to an unextended primer is low. Partial RAP inhibition in human telomerase by 
either a chemical inhibitor or a disease associated TERT mutation causes telomere shortening, 
which suggests that RAP is necessary for telomerase mediated telomere length maintenance 46,47.  
 
1.3.4.2 Template boundary definition 
 
For accurate repeat synthesis, the telomerase active site must only copy a restricted region 
of TR as the template. In human telomerase, the active site relies on primer-template base pairing, 
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which allows elongation of an annealed primer-template duplex containing only the remaining 
template region as single stranded RNA 23. The first 5 nucleotides of the RNA template bind to the 
telomeric DNA forming an RNA-DNA duplex. This enables primer alignment at the beginning of 
the template rather than the end, which is an important feature of internal template use 48. Template 
stabilization at the 3’ end of the duplex in the active site requires the TEN domain, making it a 
critical component for RAP. Accurate template use also requires DNA synthesis to halt at the 
template 5’ end 49. For human telomerase, the template 5’ boundary determination mechanism 
makes less of a contribution than the sequence of the template-product duplex 50.  
 
1.3.4.3  Base pair melting between the product and template.  
 
The product-template duplex must melt for telomerase to dissociate from an elongated 
chromosome and recycle the RNA template. Several thermodynamic models of duplex melting 
have been proposed which are covered in this section. Single molecule fluorescence resonance 
energy transfer (FRET) and biochemical experiments suggest an accordion model in which the 
TBE and template recognition element expand and contract to allow the template to move during 
the catalytic cycle 51. Another model suggests that after synthesis of a telomeric repeat the newly 
added GT rich DNA loops out into a non-canonical hairpin, while the template translocations to 
pair with the AG at the 3’ end. The incoming dGTP allows the DNA to realign in order for 
synthesis to proceed 52.  Determining the change in state that is the rate limiting barrier to the 
product-template unpairing requires more knowledge of the telomerase catalytic cycle.   
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1.3.4.4 DNA product handling independent of template base pairing.  
 
During strand separation, telomerase must retain the DNA product to avoid complete 
substrate dissociation. Since the DNA is unpaired from its TR template during this step of the 
cycle, the enzyme-product interaction is distinct from typical primer-template Watson-Crick base 
pairing 53. This interaction defines the telomerase anchor site. The telomerase anchor site allows 
the enzyme to reposition the unpaired template relative to the active site, which is followed by the 
formation of a new primer-template duplex. The new duplex can then be re-engaged by the active 
site for synthesis of the next repeat. Another function of the anchor site may be to control when 
and how during the catalytic cycle the product DNA is released from the enzyme, however there 
is no conclusive evidence. Recently, a single molecule telomerase activity assay was developed 
using high resolution optical tweezers 54. This assay measured stepwise, processive telomerase 
activity and monitored conformational dynamics of the product DNA. Telomerase can tightly 
associate with its DNA substrate, and synthesize multiple telomeric repeats before releasing them 
in a single step. The rate at which the product is released from the anchor site corresponds to the 
overall rate of product dissociation from elongating telomerase, which suggests that the anchor 
site is the main substrate binding site during telomere elongation 54.  
1.3.4.5 POT1-TPP1 Stimulation 
 
The addition of both purified POT1 and TPP1 to telomerase reactions result in a two-fold 
increase in telomerase processivity, whereas addition of TPP1 alone results in a twofold increase 
in telomerase processivity 55. POT1-TPP1 is able to increase telomerase repeat processivity by 
decreasing complete dissociation from the telomere substrate and product and by improving 
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template translocation. Additionally, only a single POT1-TPP1 DNA interaction is necessary and 
sufficient to stimulate telomerase processivity, which suggests that once the POT1-TPP1 
telomerase complex is bound to the single stranded telomeric DNA, it is maintained throughout 
the entire telomerase elongation process, independent of additional POT1-DNA binding events 56. 
1.4 Telomeres, aging, and cancer 
As we age, our telomeres progressively shorten. Age, environmental factors, and lifestyle 
(diet, smoking, stress) are associated with shortened telomeres. Short telomeres cause an increased 
risk for an array of aging-related diseases such as cancer, cardiovascular disease, diabetes, 
neurodegenerative diseases, liver cirrhosis, and hypertension 57-60. Critically short telomeres 
trigger a p53 dependent DNA damage response that leads to a state of irreversible cell growth 
arrest called replicative senescence (Figure 5). At this point, senescence is a critical protective 
mechanism for the cells to preserve the genome and prevent further proliferation of cells that may 
have genetic modifications 61-63. Senescent human fibroblasts have an activated DNA damage 
response, which includes the protein kinase ataxia-telangiectasia mutated (ATM) and ataxia 
telangiectasia and Rad3-related protein (ATR) signaling, and nuclear foci containing DNA damage 
markers including  -H2AX (phosphorylation of serine 139 on histone H2AX), p53-binding protein 
1 (53BP1) and mediator of DNA damage checkpoint protein (MDC1) 64. The upregulation of p53 
and cyclin dependent kinase inhibitors p31 and p16 are additional indicators of an activated DNA 
damage response. Senescent cells are usually in G1 phase, which is consistent with p53 activation 
and induction of the CDK inhibitors p21 and p16 65. Both the upregulation of p16 and hypo 
phosphorylation of the tumor suppressor RB can contribute to telomere-induced senescence66.  
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 Premalignant cells lacking a functional p53 and RB tumor suppressor pathways bypass 
senescence and continue to divide. At this point, cells have completely eroded their telomeres and 
their chromosome ends fuse, which can lead to genomic instability, chromosome bridge-breakage-
fusion cycles, and eventually apoptosis 67. The uncapped telomere ends are processed by DNA 
double strand break pathways which lead to chromosome fusions and instability, killing most cells 
68. The surviving cells undergo malignant transformation, which in most cases, upregulates
telomerase or the  alternative lengthening of telomeres (ALT) pathway to maintain the shortened 
telomeres and promote cellular immortalization 69.  
Figure 5. Telomere length vs. number of cell divisions. Somatic cells that do not express telomerase 
experience telomere shortening with each cell divison. When telomeres become shorter, they induce a signal 
to enter into senescence (growth arrest). When telomeres have excessive chromosome instability, they enter 
crisis. Cells are able to survive crisis by activating telomerase or the ALT mechanism to stabilize telomere 
length, causing malignant transformation. Created with Biorender. 
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1.4.1 hTERT regulation in cancer 
Telomerase upregulation or reactivation occurs in 90% of cancers, and is found in almost 
all tumor types 70. In most cancer cases, telomerase activity is present in the tumor and absent in 
normal cells71. Many malignant tumors are characterized by telomerase expression, causing 
unlimited cell proliferation 72. Most benign or premalignant tumors are characterized by an absence 
of telomerase. The most common non coding mutations found across all cancers are somatic 
mutations to the proximal hTERT promoter. Studies have shown that melanomas, glioblastomas, 
liposarcomas, and urothelial cancers contain the more frequent hTERT promoter mutations 
compared to other cancer types 69,73-76. The hTERT promoter mutations activate telomerase activity 
by converting the conserved regions in the hTERT promoter to an ETS transcription factor binding 
site. As a result of this dysregulation, these cancerous cells produce levels of telomerase high 
enough to enable them to continuously divide without limitation.  
1.4.1.1 hTERT promoter mutations 
The hTERT promoter is GC rich and lacks a TATA box, which is typically found in the 
promotor regions of genes that encode proteins found in eukaryotes 77. The promoter contains 
multiple binding sites for transcription factors, which suggests that hTERT expression is under 
many levels of control and may be regulated by multiple factors. The promoter core is a 260 bp 
proximal region and is responsible for transcriptional activity. It contains five GC boxes 
(GGGCGG), which bind to the zinc finger transcription factor SP1, which is essential for hTERT 
promoter activity 78,79. It has been shown that formation of secondary DNA G-quadruplex 
structures in the GC boxes masks the SP1 binding site which can also cause hTERT promoter 
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repression. Therefore, transcriptional up-regulation or reactivation of hTERT is a crucial step in 
tumorigenesis and there are multiple mechanisms which reactivate hTERT in cancer 78. These 
mechanisms include the mutation or deletion of the hTERT promoter, gene amplification, 
epigenetic alterations, and hTERT gene alterative splicing factors 79. 
Recent whole genome sequencing experiments demonstrate that expression of the hTERT 
gene is reactivated by single nucleotide mutations in the proximal promoter of the hTERT gene 
80,81. These mutations modulate transcriptional regulation without altering the encoding of the 
hTERT protein. They consist of a cytosine to thymidine transition at the -124bp and 146bp 
upstream of the translation start site and are very close in proximity to the transcription start site 
of the hTERT gene. Additionally, they are located in the GC-boxes of the hTERT core promoter 
77.  
 hTERT promoter mutations are less common in lung, breast, esophageal, colon, and 
prostate cancers because they generate a consensus binding motif (CCGGAA) at the E-twenty-six 
(ETS) transcription factors 74. The location of these mutations creates additional binding sites for 
ETS, which is a novel mechanism of gene activation in cancer, and genomic alteration driver 81. 
ETS transcription factor binding to the motifs created by the hTERT mutations cause recruitment 
of a multimeric ETS family member, the GA-binding protein alpha subunit (GABPA) that 
activates hTERT transcription 82. GABPA has been identified as the binding factor in most cancer 
cells with TERT promoter mutations 79. Because these mutations are prevalent in many cancer 
types, hTERT is an attractive therapeutic target to halt the proliferation of cancer cells.  
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1.5 Roles of oxidative stress in telomere length homeostasis 
1.5.1 Reactive oxygen species 
Oxidative stress is caused by an excess of reactive oxygen species (ROS), caused by 
exogenous (UV, ionizing radiation, chemicals) and endogenous sources. Inflammation and 
mitochondrial dysfunction are the main endogenous ROS sources. Mitochondrial ROS arise from 
incomplete reduction of O2 during oxidative phosphorylation to produce superoxide radical O2-, 
rather than completely reduced to water 58. If the cell cannot remove ROS by its antioxidant 
enzymes, the ROS can damage different cellular components through aberrant oxidation of nucleic 
acids, lipids, and proteins. Oxidative damage causes the majority of DNA damage in human cells, 
appearing as an oxidized base, sugar modification, DNA or protein crosslink, or DNA strand break 
83. Guanine is the most susceptible of the DNA bases to oxidation because it has the lowest
oxidation potential. This results in the oxidation of guanine to form 8-oxoguanine 84, which is the 
most abundant oxidized base that arises from ROS exposure 85. 8-oxoguanine is a highly mutagenic 
base because the presence of an unrepaired oxidized base in the DNA can be bypassed by DNA 
polymerases, which typically introduce dAMP opposite 8-oxoG instead of the canonical dCMP. 
Thus, inducing a G:C-T:A transversion mutation results in genomic instability 86. The oxidation 
of guanine also occurs in the free dNTP pool which are the precursors for DNA synthesis.  DNA 
polymerase incorporation of 8-oxodGTP opposite dC or dA on the template strand can induce a 
A:T-C:G transversion during subsequent replication. Oxidative stress inducing base modifications 
and single strand breaks can interfere with the replication machinery and are able to activate the 
DNA damage response 87.  
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While telomeres only make up a small percentage of the genome, they are highly 
susceptible to oxidative damage because they are rich in guanine. Numerous studies have shown 
that oxidative stress leads to accelerated telomere shortening 88. Not only does ROS induced 
damage interfere with replication of telomeric DNA 89, but also the oxidatively damaged DNA and 
free oxidized dNTPs used for telomere synthesis can interfere with telomerase activity 90. The 
Opresko lab and others have previously shown that 8-oxo-dGTP is used by human telomerase as 
a substrate and following incorporation  into the DNA it functions as a chain terminator 91,92.  
1.5.1.1 Protecting telomeres from ROS  
 
There are several enzymatic pathways that protect telomeres from ROS. Nucleotide pool 
sanitation enzymes help eliminate oxidized dNTPs and work in parallel with the DNA repair 
machinery to maintain genome integrity. The most common sanitation enzymes are the nucleoside 
diphosphate linked with some moiety X (Nudix) hydrolase family 93. These enzymes work by 
catalyzing the hydrolysis of nucleoside-like di- or triphosphates to their respective 
monophosphates. The core residues of the enzyme’s catalytic domain are required for divalent 
cation coordination, which is essential for catalysis, however they do not discriminate or direct the 
nucleobases, which suggests there is a flexibility within the super family.  
The most studied sanitation enzyme today is NUDT1 (Nudix type 1), also known as MutT 
homolog 1 (MTH1). MTH1 hydrolyses oxidized nucleotides 8-Oxo-7,8-dihydro-2'-
deoxyguanosine 5'-triphosphate, 2-Hydroxy-2’-deoxyadenosine-5’-triphosphate, and 8-Hydroxy-
2'-deoxyadenosine-5'-triphosphate (8-oxo-dGTP, 2-OH-dATP, and 8-oxo-dATP respectively) to 
monophosphates (dNMP), thereby avoiding their incorporation into DNA by DNA polymerases 
(Figure 6) 86,94-97. MTH1 is an important enzyme in maintaining genomic integrity and replicative 
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potential in cultured fibroblasts and oncogenic Ras transformed cells 98-100. MTH1 is also a 
promising drug target in cancer cells, where a dysfunctional redox environment can lead to a 
dependency on oxidized nucleotide sanitation for cell survival 101-103.  The Opresko lab and others 
previously reported that MTH1 depletion inhibits telomere maintenance and telomerase activity in 
cancer cells grown under oxidative stress conditions, and that telomerase insertion of 8-oxo-dGTP 
terminates further telomere elongation in vitro 91,92,104.  However, since MTH1 also removes 
oxidized dATPs, whether these damaged nucleotides can inhibit telomerase activity, similar to 8-
oxo-dGTP, and contribute to telomere shortening had been unknown until my work on this topic. 
Figure 6. MTH1 pathway. ROS oxidizes the free physiological nucletides dGTP and dATP into 8-oxo-dGTP 
and 2-OH-dATP. MTH1 hydrolyzes the oxidized dNTPs into 8-oxo-dGMP and 2-OH-dAMP so that they 
cannot be incorporated into DNA. Oxidized nucleotides incorporated into the DNA cause DNA damage. 
Created with Biorender.
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1.6 Telomerase inhibitors 
Telomerase is a prime target for effective cancer therapeutics since it is expressed in over 
90% of cancers. Cancer cells have short telomeres because they have gone through extensive 
telomere shortening before emerging from crisis, then telomerase can maintain their telomeres at 
shortened lengths 105. Non-cancer cells, including stem cells, have lower telomerase activity and 
normally maintain telomeres at longer lengths than cancer cells. This is advantageous because it 
suggests telomerase inhibition should deplete telomeres more rapidly in highly proliferating cancer 
cells with short telomeres, while reducing the risk for extensive telomere shortening in non-cancer 
cells. In most cancer cases, telomerase activity is present in the tumors and absent in telomerase 
silent normal cells. Since telomerase is activated due to mutations in the non-coding hTERT 
promoter region, the goal of anti-telomerase therapeutics is to selectively induce apoptosis and cell 
death in cancer cells but minimize the effects on non-cancer cells 105. There are several types of 
therapeutic telomerase inhibitors including vaccines using a telomerase specific peptide which 
causes an anti-telomerase immune response, antisense oligonucleotides, modified dNTPs, and 
small molecule inhibitors of hTERT or hTR.  
The most extensively studied telomerase inhibitors to date are Imetelstat (GRN163L) and 
the BIBR1532 compound. Imetelstat, which is a 13-mer thiophosphoramidate oligonucleotide, 
binds with high affinity to hTR template of telomerase, resulting in direct, competitive inhibition 
of telomerase in a dose dependent manner 106. In several cancer cell lines, Imetelstat induced 
growth arrest and caused telomere shortening 107,108. Clinical studies on patients with advanced 
non-small cell lung cancer showed limited improvement, and for pediatric patients with brain 
cancer, the drug could only be administered for two weeks before the toxicity levels became 
intolerable 108. Unfortunately, the long period of time required for Imetelstat to shorten the 
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telomere length in patients caused hematologic and hepatotoxic dose-limited side effects 109. When 
patients took time off from drug, due to the toxicities, they had reestablishment of their telomere 
length in their tumors and continued cell growth 110. One report showed that 2 weeks after 
termination of Imetelstat, A549-Luc cells (lung carcinoma),  were able to reform colonies at the 
same rate as before treatment with the drug 106.  
BIBR1532 is a non-nucleotidic synthetic small molecule drug and has been shown to be a 
selective inhibitor of telomerase 111. BIBR1532 acts as a mixed-type noncompetitive inhibitor and 
interacts with the hydrophobic pocket of the thumb domain of telomerase, which reduces 
telomerase processivity. BIBR1532 can induce apoptosis in various breast cancer cell lines. The 
molecular mechanism of BIB1532 inhibition remains to be understood in more detail, and it 
suppresses cell survival and further activates apoptotic associated factors such as p73, caspase-3, 
and Bax/Bcl-2 112. According to clinicaltrials.gov, there are no ongoing clinical trials of 
BIBR1532, likely due to tissue toxicities in normal cells 112.  
 
Table 1. Comparison of HIV-1 and Telomerase 
 
HIV-1 reverse transcriptase Telomerase 
Organism HIV-1 Virus Humans 
Structure Fingers, thumb, and palm 
domains + RNase H 
Fingers, thumb, and palm domains 
Template Viral RNA Telomerase RNA template 
Final 
product 
Double stranded DNA used 
for viral integration into the 
host DNA  
Double stranded TTAGGG repeats 




1.6.1 Telomerase therapeutics: Nucleoside analogs   
Another strategy to target telomerase in cancer cells is to introduce a modified nucleoside 
so that telomerase can preferentially incorporate the modified dNTP into telomeric DNA in order 
to halt further telomere elongation. An altered nucleotide which is incorporated into telomeres 
would not bind to shelterin properly and could cause telomere dysfunction and rapid cell death. 
Nucleoside analogs are commonly used in a wide range of antiviral therapies to prevent viral 
replication in infected cells. Once they are incorporated into DNA, they are chain terminators and 
stop the viral polymerase from extending the chain of DNA.  Several nucleoside analogs have also 
been tested as cancer therapeutics, which will be discussed in the next several sections. 
1.6.2 Nucleoside reverse transcriptase inhibitors  
Nucleoside reverse transcriptase inhibitors (NRTIs) block the reverse transcription of HIV-
1 viral RNA. In their phosphorylated form, NRTIs compete with natural dNTPs for insertion by 
HIV-1 RT, and act as chain terminators 113. The catalytic core of TERT is structurally homologous 
to the HIV-1 RT domain (Table 1) 114, and telomerase inhibition has been proposed to contribute 
to premature aging observed in HIV patients undergoing long term NRTI therapy 115,116. While 
previous studies have confirmed that treatments with various NRTIs cause telomere shortening 
and inhibit telomerase in vitro 117-119, whether telomerase can insert these chain terminating 
analogs during telomere synthesis had not been tested until this dissertation. 
Accumulation of mitochondrial DNA mutations, increased mitochondrial oxidative stress, 
and a decrease in mitochondrial energy metabolisms contribute to aging120. NRTIs not only act as 
HIV chain terminators but can also inhibit mitochondrial DNA (mtDNA) polymerase γ (pol γ), 
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which disrupts mitochondrial DNA replication and induces mitochondria dysfunction (Figure 7) 
121. Inhibition of pol γ leads to the depletion of mtDNA, and subsequent depletion of mtRNA and 
of mitochondria encoded polypeptides involved in oxidative phosphorylation. This discovery led 
to the theory of NRTI-induced toxicity known as the “polymerase γ theory” 120.  When NRTIs 
cause a decrease in mtDNA, the electron transport chain proteins are depleted, causing changes in 
respiration rate, decreased ATP production, diminished mitochondria membrane potential, and an 
increase in ROS production. NRTIs can also obstruct base excision repair and proof-reading 
capabilities of pol γ. Studies showed that mice with impaired pol γ proofreading had accumulation 
of mtDNA mutations which led to disrupted mitochondrial function, several aging phenotypes, 
and cell death 122. NRTI mediated increase in ROS via mitochondrial dysfunction has the potential 




1.6.3 AZT as a potential cancer therapeutic  
3-Azido-2, 3-dideoxythymidine (AZT), clinically referred to as Zidovudine, is a thymidine 
analog synthesized in the 1960s as a potential anti-cancer agent, however at the time, it failed to 
be an effective cancer therapeutic 123. When HIV was discovered in the 1980s, AZT was one of 
the first drugs shown to be a potent inhibitor of retroviruses. AZT is phosphorylated intracellularly 
to AZT-triphosphate (AZT-TP) by thymidine kinase, and is then integrated into viral DNA, 
causing chain termination.  
Figure 7. NRTI induced mitochondrial toxicity. The dNTP form of NRTIs inhibits mitochondrial DNA 
polymerase gamma, which is a polymerase necessary for the normal replication of mitochondrial DNA. 
Mitochondrial DNA depletion causes elevated levels of ROS which can cause mitochondrial dysfunction and 
cell death. Created with Biorender. 
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When telomerase was discovered, questions were raised asking if AZT could be a cancer 
therapeutic.  In 1994, Strahl and Blackburn demonstrated that AZT can preferentially incorporate 
into telomeric DNA of Tetrahymena, and cause telomere shortening 117. During the same year, 
another group demonstrated strong links between telomerase activity and cancer 70. AZT-TP can 
be incorporated into eukaryotic DNA in place of thymidine, although it has low affinity for DNA 
polymerases α, β and γ, but a high affinity for reverse transcriptases 124. These two studies led to 
the hypothesis that AZT could inhibit telomerase in cancer cells. Strahl and Blackburn later 
demonstrated that AZT could inhibit telomerase and reduce telomere length in two immortalized 
human lymphoid cell lines 118. They found that passaging the cells with 100 μM AZT caused 
progressive telomere shortening in most of the lymphoid cultures, but the treatment did not change 
the cell growth rates, suggesting that AZT was preferentially being incorporated by telomerase 
rather than by replicative polymerases. 118. In immortal mouse fibroblast cultures, AZT induced 
senescence 125. 
 In 2001, the effects of chronic in vitro AZT treatment on mouse mammary carcinoma cell 
lines showed that AZT treatment for over 30 passages inhibited telomerase activity, caused 
progressive telomere shortening, and led to cellular senescence and apoptosis 46,126. This study 
demonstrated for the first time that AZT-treated tumor cells had reduced tumorigenicity in BALB/c 
mice. Tumors volumes were reduced and survival was longer in animals inoculated with AZT-
treated tumor cells compared to the control. Additional studies showed that AZT reduced tumor 
growth in parathyroid cancer cells and hepatocellular carcinoma in rats 127. AZT is currently used 
for the treatment of several virus associated human cancers, including Epstein-Barr-associated 
lymphoma, AIDS-related Kaposi sarcoma, primary central nervous system lymphoma, Kaposi 
sarcoma-associated primary effusion lymphoma, and adult T cell leukemia 123. According to 
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clincialtrials.gov, there are five ongoing phase I and II clinical trials investigating AZT treatment 
alone or a combination with other drugs in the treatment of breast cancers and lymphomas.  
1.6.4 Thiopurines 
Thiopurines are a class of therapeutic nucleoside analogs that cause telomere shortening 
128, and are currently used in clinical practice as antileukemic, anti-inflammatory, and 
immunosuppressive agents 129. Their uses for cancer therapy have been limited to leukemia and 
some pediatric cancers due high levels of toxicity. In cells, thiopurines are first metabolized to 6-
thioguanosine monophosphate and then further metabolized to 6-thio-2’deoxyguanosine-
5’triphosphate (6-thio-dGTP). This molecule can then be incorporated into DNA during 
replication 130. 6-thio-dGTP is also readily incorporated into mitochondrial DNA, where it is 
rapidly oxidized 131. Accumulation of oxidized 6-thioguanine is associated with pol γ inhibition, 
reduced mtDNA transcription, decline in mitochondrial protein levels, and loss of mitochondrial 
function.  Both of these instances may generate high levels of ROS, which can cause additional 
damage to the DNA and block cellular replication 132. 
Recently, a nucleoside analog of 6-thioguanine, 6-thio-2’deoxyguanosine, (6-thio-dG) was 
designed with the hypothesis that it may be preferentially recognized by telomerase and be 
incorporated into telomeric DNA 128. Because telomeres are G rich, the O6 sulfur moiety in the 6-
thio-groups mimic guanines, but they result in an altered chemical structure, and the Shay lab 
reasoned that if the drug can be incorporated into telomeric DNA, it may impede the function of 
the shelterin complex. If the shelterin protein, TRF2, is compromised, telomeres may be falsely 
recognized as DNA double strand breaks and acquire DNA-damage signals which can be detected 
using immunofluorescence techniques 133. The damage signals are telomere associated, and 
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referred to as telomere dysfunction-induced foci (TIF). TIFs can be visualized by the 
colocalization of DNA damage response factors such as 53BP1 and the histone family member, γ 
-H2AX 134. Compared to cancer cells treated with 6-thioguanine,  after 72 hours, 6-thio-dG caused 
7.8 times more TIFs 128. When added at equal concentrations to non-cancer cells, 6-thio-dG is 
significantly less toxic to the cells than 6-thioguanine 128. Compared to other telomerase inhibitors, 
6-thio-dG decreases the lag period in telomere shortening. It also does not have a significant effect 
on telomerase deficient cells 128.  
Clinically relevant studies have shown that 6-thio-dG can control the progression of disease 
for longer periods in pre-clinical models of melanoma that were resistant to targeted therapies or 
immunotherapies 135. The studies analyzed 6-thio-dG in combination with targeted therapies using 
BRAF inhibitors or as a monotherapy with BIBR1532. When 6-thio-dG was used as a 
monotherapy, it was more effective than BIBR1532 in causing anti-proliferation of BRAF mutant 
melanoma cell lines and did not cause any hematological or hepatotoxicities in mice. Importantly, 
6-thio-dG was similar to the BRAF inhibitor, PLX4720, and halted tumor growth in xenograft 
models. Additional pre-clinical studies have shown that 6-thio-dG could overcome chemotherapy 
resistance in both lung cancers and therapy resistant pediatric brain cancer 136,137.  
The previous reports demonstrated that 6-thio-dGTP promotes cell death in telomerase 
positive cancer cells, and decreases tumor growth in mouse xenograft studies 128.  6-thio-dG 
treatment causes telomere shortening and telomere dysfunction, but the mechanism is unclear 
because extracts from treated cells do not show reduced telomerase activity 128. 
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1.6.5 Recent FDA approved cancer therapeutic dNTPs 
5-flouro-2’deoxyuridine (5-FDU) is an FDA approved agent used for the treatment of 
metastatic colon and liver cancers. 5-FdU causes a similar cytotoxicity as 5-floururacil (5-FU) 
after administration in vivo 138. The metabolites from the drug inhibit thymidylate synthase to 
deplete cellular deoxythymidine pools, which impairs DNA replication and repair. In the cell, the 
metabolites are converted into nucleotides, which are then misincorporated into DNA and RNA to 
cause cytotoxic effects. A recent study demonstrated that when several modified nucleotide 
analogs, including 5-FdU, were replaced with the natural form of the analog,  telomerase activity 
was inhibited 137.  When 5-FdU was substituted into the telomere DNA sequence, POT1-TPP1 
binding to the DNA substrate was impaired. 5-FdU  is cytotoxic to telomerase positive cancer cells 
and promotes telomerase inhibition, without initiating cytotoxic mechanisms with selectively low 
doses of the drug, suggesting that the dosing regimen is highly selective for telomerase positive 
cancers and has minimal effects on somatic cell populations 137. The Taylor group also indicated 
that the cytotoxicity of 5-FdU is telomerase dependent and that its incorporation into telomeric 
DNA caused a DNA-damage response resulting in cell death within a few days in vitro 137. This 
study expanded our understanding of how the anti-cancer drug 5-FdU, as well as several other 
pyrimidines with modifications at the 5-position of the nucleobase could limit telomerase activity 
in vitro and was cytotoxic in telomerase positive cancer cells.   
The Taylor group also screened several indollyll-2’deoxynucleotide analogs with different 
chemical modifications to determine if they could be incorporated into telomeres 137.  The analogs 
were designed to mimic the structure of dATP, but had various functional groups introduced at the 
5 or 6 position of the indole ring to modulate biophysical features such as hydrophobicity, size 
variation, shape, and election density. Additionally, these modified analogs disrupted proper 
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Watson-Crick base pairing with the telomerase RNA template. They found that the nucleotide 5-
methycarboxyl-indoly-2’deoxyriboside 5’-triphosphate (5-MeCITP) inhibited telomerase activity 
in vitro. Using structural studies, they determined that the analog binds to the TERT active site 
when the nucleobase was inverted so that the methyl carboxyl modification interacted with the 
telomerase specific hydrophobic pocket adjacent to the TERT active site. When they administered 
a permeable form of 5-MeCITP, they found evidence for telomerase dependent telomere 
shortening in cancer cells. When compared to AZT-TP, administration of 5-MeCITP inhibits 
telomerase activity with a similar potency. Compared to AZT, 5-MeCIdR was better tolerated by 
normal telomerase deficient cells and had minimal changes in cell viability. Their data suggested 
that 5-MeCIdR treatment was better tolerated by cells than AZT, perhaps due to higher selectivity 
that limits off target effects on metabolic pathways and non-telomerase polymerases 137.  
 
1.6.6 Treatment with therapeutic dNTPs may avoid the ALT pathway 
One caveat to traditional non-nucleoside telomerase inhibitors is that following inhibition, 
cancer cells must undergo multiple population doublings for the telomeres to shorten enough to 
trigger replicative senescence or crisis 139. This delay may allow activation of resistance 
mechanisms, such as the alternative lengthening of telomeres (ALT) pathway, which is telomerase 
independent and instead relies on homologous recombination events at the telomere to restore 
telomere lengths 140.  Because telomerase mediated misincorporation of modified nucleosides 
occurs within a few days, activation of the ALT mechanism may lessen after following chronic 
administration of telomerase inhibitors. The molecular mechanisms that initiate and maintain ALT 
are still largely unknown; however, some mechanisms of ALT inhibition have been explored. ATR 
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inhibitors, such as VE-822 and NVP-BEZ235 have been shown to selectively target and kill ALT 
positive cells 141. Therefore, to completely eliminate the ALT pathway, it may be possible to 
combine both nucleoside and ALT inhibitors as a treatment strategy.  
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2.0 Specific Aims 
2.1 Statement of Gap in Knowledge 
Numerous studies have shown that oxidative stress leads to accelerated telomere shortening 
67. The Opresko lab and others previously reported that MTH1 depletion inhibits telomere
maintenance and telomerase activity in cancer cells grown under oxidative stress conditions, and 
that telomerase insertion of 8-oxo-dGTP terminates further telomere elongation in vitro 91,92,104.  
However, MTH1 also removes oxidized dATPs, and whether these damaged nucleotides can 
inhibit telomerase activity, similar to 8-oxo-dGTP, and contribute to telomere shortening is 
unknown. While oxidized dNTPs arise naturally, synthetic modified dNTPs such as NRTIs and 
thiopurines have a long history of successful use for anti-viral and cancer therapies. While previous 
studies have confirmed that treatments with various NRTIs cause telomere shortening and inhibit 
telomerase in vitro 117-119, whether telomerase can insert these chain terminating analogs during 
telomere synthesis had not been tested. Additionally, thiopurine treatment causes telomere 
shortening and telomere dysfunction, but the mechanism is unclear because extracts from treated 
cells do not show reduced telomerase activity 128. In addition, since both NRTIs and thiopurines 
can elevate ROS by causing mitochondrial dysfunction, they can potentially increase oxidative 
damage within nucleotide pools 120,131.   Overall, the mechanisms by which these modified dNTPs 
inhibit telomerase are poorly understood.  
Hypothesis and scope: Oxidized and therapeutic dNTPS can inhibit telomerase both directly, and 
indirectly through elevated ROS induced oxidized dNTPs.  
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Approach: We isolated telomerase to perform direct telomeric DNA synthesis assays to measure 
telomerase activity and processivity to address several fundamental questions related to how the 
modified dNTPs impact the mechanism of telomeric repeat synthesis.  
 
1. Can telomerase utilize oxidized or therapeutic dNTPs for telomere elongation? We 
conducted telomerase assays in which we replaced increasing concentrations of the natural 
dNTP with the corresponding oxidized or therapeutic dNTP analog in reactions containing 
the remaining three natural dNTPs. Our data indicated that oxidatively damaged dNTPs and 
therapeutic dNTPs inhibited telomerase to varying extents.  
2. Can telomerase incorporate oxidized or therapeutic dNTPs into telomeric DNA? If so, 
is the nucleotide addition chain terminating and/or mutagenic? We previously showed 
that 8-oxo-dGTP is a telomerase chain terminator, so we wanted to determine the mechanism 
by which other oxidized or therapeutic dNTPs inhibited telomerase.  We conducted 
telomerase assays in which we radiolabeled a DNA primer to initiate DNA synthesis 
opposite various template positions and added increasing concentrations of only a single 
dNTP.  Our data indicate that the NRTIs are telomerase chain terminators, but 6-thio-dGTP 
and 2-OH-dATP are not and have distinctly different mechanisms of telomerase inhibition. 
3. If modified dNTP incorporation is not chain terminating, how does the incorporation 
impact the telomerase catalytic cycle? To better understand how 2-OH-dATP and 6-thio-
dGTP inhibit telomerase, we examined whether telomerase could incorporate a naturally 
occurring dNTP after inserting either 2-OH-dATP or 6-thio-dGTP. We found that 2-OH-
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dATP and 6-thio-dGTP interfere with the translocation step during the telomerase reaction 
and compromise further telomerase extension.   
4. Can POT1-TPP1 overcome telomerase inhibition during telomere synthesis when 
treated with oxidized or therapeutic dNTPs? POT1-TPP1 recruit telomerase to telomeres, 
and greatly increase telomerase processivity. We hypothesized that POT1-TPP1 may be able 
to overcome inhibition by the modified dNTPs and enhance telomerase processivity. We 
conducted telomerase assays with radiolabeled primers in the presence of purified POT1-
TPP1. Our results showed that POT1-TPP1 stimulation was not able to fully restore 
telomerase extension in the presence of the modified dNTPs.  
5. Are modified dNTPs able to compete with natural dNTPs for telomerase utilization? To 
gain further insight into telomerase selectivity for the modified dNTPs, we titrated increasing 
amounts of the modified dNTPs in reactions containing all of the natural dNTPs. We 
calculated the IC50 to determine the concentration of modified dNTP that reduces the 
telomerase processivity in the bulk reactions by half. The modified dNTPs varied in their 
ability to compete with natural dNTPs for utilization by telomerase, with 6-thio-dGTP having 
the lowest IC50.   
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3.0 Materials and Methods 
3.1.1 Telomerase preparation 
Telomerase was immunopurified as described previously91 with some modification. 
HEK-293T (ATCC) cells were grown to 90% confluency in Dulbecco’s modified Eagle’s medium 
(Gibco) supplemented with 10% FBS (Hyclone) and 1% penicillin-streptomycin (Corning) at 
37°C and 5% CO2. Cells were transfected with 10 μg of pSUPER-hTR plasmid and 2.5 μg of 
pVan107 hTERT plasmid diluted in 625 μl of Opti-MEM (Gibco) mixed with 25 μl of 
Lipofectamine 2000 (ThermoFisher) diluted in 625 μl of Opti-MEM. Cells expressing hTR and 
3xFLAG-tagged human hTERT were harvest 48 hr post-transfection, trypsinized and washed 
with PBS, and then lysed in CHAPS buffer (10 mM Tris-HCl, 1 mM MgCl2, 1 mM EDTA, 0.5% 
CHAPS, 10% glycerol, 5 mM β-mercaptoethanol, 120 U RNasin Plus (Promega), 1 μg/ml each 
of pepstatin, aprotinin, leupeptin and chymostatin, and 1 mM AEBSF) for 30 min at 4°C. Cell 
lysate supernatant was then flash frozen and stored at -80ºC. 
80μL of anti-FLAG M2 bead slurry (Sigma) (per T75 flask) was washed three times 
with 10 volumes of 1x human telomerase buffer (50 mM Tris-HCl, pH 8, 50 mM KCl, 1 mM 
MgCl2, 1 mM spermidine and 5 mM β-mercaptoethanol) in 30% glycerol and harvested by 
centrifugation for 1 min at 3500 r.p.m. and 4ºC. The bead slurry was added to the cell lysate 
and nutated for 4-6 hours at 4ºC. The beads were harvested by 1 min centrifugation at 3500 
r.p.m, and washed 3X with 1X human telomerase buffer with 30% glycerol. Telomerase was
eluted from the beads with a 2x the bead volume of 250 μg/mL 3X FLAG® peptide (Sigma 
Aldrich) in 1X telomerase buffer containing 150 mM KCl. The bead slurry was nutated for 30 
 38 
min at 4ºC. The eluted telomerase was collected using Mini Bio-Spin® Chromatography columns 
(Bio-Rad).  Samples were flash frozen and stored a -80ºC.  
3.1.2 Dot blot quantification of telomerase concentration 
The concentration of telomerase pseudoknot RNA in the eluted telomerase preparation 
was measured as described previously142.  Briefly, a serial dilution of in-vitro transcribed 
pseudoknot region of hTR (Supplementary Fig. 1) was prepared as standards for quantification 
(0.1, 0.5, 1, 5, 10, 50, 100, 250 fmol/μL). An aliquot of each standard and eluted telomerase (10 
l) was added to 90 l of formamide buffer (90% formamide, 1X TBE). The samples were 
incubated at 70ºC for 10 minutes and then placed on ice. Positively charged Hybond H+ 
membranes and Whatman filter papers (GE Healthcare Life Sciences) pre-incubated with 1X 
TBE were assembled onto the GE manifold dot blot apparatus and the samples were loaded 
onto the membrane via vacuum blotting. The membrane was air dried and then UV-crosslinked 
using a Stratagene Stratalinker 1800 with the Auto-Crosslink program. The membrane was 
prehybridized at 55ºC in 25 ml of Church buffer (1%BSA, 1mM EDTA pH 7.5, 500mM 
Na2HPO4 pH 7.2, 7% SDS) for 30 minutes. A total of 1x106 CPM of 32P labeled hTR 
oligonucleotide probe (Supplementary Table 1) was added to the hybridization buffer and 
incubated overnight at 55ºC. The membrane was washed 3X with 0.1xSSC, 0.1xSDS buffer. 
After vacuum sealing, the membrane was exposed to a phosphorimager screen for 1-3 hours 
and imaged using a Typhoon scanner. Image quant TL was used to quantify the blot intensities 
for the standard curve.  
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3.1.3 32P-end-labeling of DNA primers  
50 pmol of PAGE purified DNA oligonucleotides (IDT) (Supplementary Table 1) was 
labeled with γ32P ATP (Perkin Elmer) using T4 polynucleotide kinase (NEB) in 1X PNK Buffer 
(70mM Tris-HCl, pH 7.6, 10mM MgCL2, 5mM DTT) in a 20 l reaction volume. The reaction 
was incubated for 1 h at 37ºC followed by heat inactivation at 65ºC for 20 minutes. G-25 spin 
columns (GE Healthcare) were used to purify the end labeled primer.  
3.1.4 Telomerase activity assay with radiolabeled dNTPs 
The telomerase assay was as previously described 91. Reactions (20 μl) contained 1x human 
telomerase buffer, 1 μM oligonucleotide substrate and dNTP mix as indicated in the figure legends. 
Reactions with cellular dNTP concentrations contained 24 μM dATP, 29 μM dCTP, 37 μM dTTP, 
5.2 μM dGTP and 0.3 μM 3,000Ci/mmol [α-32P]dGTP or [α32P] dTTP (PerkinElmer) as indicated. 
Reactions containing the modified dNTPs (Trilink Biotechnologies) substituted for their natural 
dNTP analog are indicated in the figure legends. The reactions were started by the addition of 3 μl 
(~35 fmol) of immunopurified telomerase eluent, incubated at 37ºC for 1 hour, then terminated 
with 2 μl of 0.5 mM EDTA and heat inactivated at 65ºC for 20 minutes. 32P-end-labeled 18 mer 
loading control (8 fmol) was added to the terminated reactions before purification with an Illustra 
Microspin G-25 column (GE Healthcare). An equal volume of loading buffer (94% formamide, 
0.1 × Tris-borate-EDTA [TBE], 0.1% bromophenol blue, 0.1% xylene cyanol) was added to the 
reaction eluent from the G-25 spin column. The samples were heat denatured for 10 min at 100°C 
and loaded onto a 14% denaturing polyacrylamide gel (7M urea, 1x TBE) and electrophoresed for 
90 min at constant 38W. Samples were imaged using a Typhoon phosphorimager (GE Healthcare). 
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Gels were quantitated using Image Quant TL. The processivity was calculated as previously 
described55.   
3.1.5 Telomerase activity assay with end labeled primers 
Reactions (20 μl) contained 1x human telomerase buffer, 5 nM of 32P-end-labeled primer 
and dNTPs as indicated in the figure legends. The reactions were started by the addition of 3 μl of 
immunopurified telomerase eluent, incubated at 37ºC for 1 hour, then terminated with 2 μl of 
0.5mM EDTA and heat inactivated at 65ºC for 20 minutes. An equal volume of loading buffer 
(94% formamide, 0.1 × Tris-borate-EDTA [TBE], 0.1% bromophenol blue, 0.1% xylene cyanol) 
was added to the reaction eluent. The samples were heat denatured for 10 min at 100°C and loaded 
onto a 14% denaturing acrylamide gel (7M urea, 1x TBE) and electrophoresed for 90 min at 
constant 38W. Samples were imaged using a Typhoon phosphorimager (GE Healthcare). Percent 
primer extension was calculated with ImageQuant by measuring the intensity of each product band 
and dividing by the total radioactivity in the lane or total products, as indicated in the figure 
legends.  
3.1.6 Quantitation 
All gels were quantitated using Image Quant TL. Repeat processivity from the direct 
telomerase extension assays was calculated as R1/2 (equivalent to the half-time for decay in an 
exponential time course), which represents the median length of DNA product formed, expressed 
in terms of number of telomere repeats. First, the total volume counts for each product band extend 
by one or more telomere repeats were obtained using Image Quant TL. The volume counts were 
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then normalized by dividing by the number of radiolabeled guanosines incorporated into the 
extended products based on the number of repeats added, termed corrected volume (corr vol). The 
“percent left behind” (%LB) was calculated for each product band by summing the counts for that 
product band and for every product band below (shorter products), divided by the total counts for 
the lane, and then multiplied by 100. The natural log of (100 - %LB) was calculated and then 
plotted vs. repeat number for each product length. A linear regression line was fit to the data to 
determine the slope of the line. The R1/2 value was calculated by dividing -ln(2) by the slope of 
each fitted line (R1/2 = -ln(2)/slope). 
For the primer extension calculations, the intensity of the products and unextended primer 
were measured and corrected for background in the no enzyme control (P) reactions. The percent 
primer extension was calculated as the amount of extended products divided by the total 
radioactivity in the lane. The percent total product was calculated as the amount the signal intensity 
of each individual band (nucleotide) divided by the amount of total product extended. 
3.1.7 POT1/TPP1 purification 
Full-length human POT1 was expressed as a SUMOstar-hexahistine- POT1 fusion protein 
in baculovirus-infected SF9 cells (Thermo Fisher Scientific), as described143. Sf9 insect cells 
expressing recombinant POT1 were lysed in buffer (25 mM Tris pH 8.0, 500 mM NaCl, 10 mM 
imidazole) with a protease inhibitor cocktail (Roche Molecular Biochemicals).  Subsequent buffers 
contained protease inhibitors 2 g ml-1 each of aprotinin, leupeptin, chymostatin, and pepstatin, 1 
mM AEBSF and 5 mM -mercaptoethanol. Following sonication, the lysate was centrifuged at 
40,000 r.p.m. for 75 min at 4oC. The supernatant was filtered through a 0.2 micron filter and loaded 
onto a HisTrap FF column (GE LifeSciences), followed by washing and elution with 20 and 200 
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mM imidazole, respectively, using an ATKA Pure FPLC (GE Healthcare).  Fractions containing 
POT1 were pooled and incubated with SUMOstar protease (Ulp1 variant, LifeSensors) for one 
hour with gentle mixing by rotation 20 r.p.m. at room temperature to cleave the histidine tag. POT1 
was separated from the protease and cleaved tag by size exclusion FPLC chromatography. Samples 
were loaded on a HiLoad 16/600 Superdex 200 column (GE Healthcare) equilibrated with 25 mM 
Tris pH 8.0, 150 mM NaCl, 5 mM DTT and protease inhibitors.  Eluted fractions containing POT1 
were collected and pooled. Purified TPP1-N (amino acids 89-334) protein was obtained from 
soluble lysates of isopropyl β-d-thiogalactopyranoside-induced BL21(DE3) pLysS cells 
(Promega) after nickel agarose chromatography, treatment with Ulp1 protease to cleave the Smt3 
tag31 and size exclusion chromatography as described56. Expression was induced with 0.8 mM 
IPTG in cells for about 13 hours at 24oC, and then harvested by centrifugation at 4500 rpm for 20 
min. Cell pellets were lysed in buffer (20 mM Tris pH 7.5, 500 mM NaCl, 10 mM imidazole) with 
a protease inhibitor cocktail (Roche Molecular Biochemicals).  Following sonication, the lysate 
was centrifuged 40,000 rpm for 75 min at 4 °C. The supernatant was filtered through a 0.2 micron 
filter and loaded onto a HisTrap FF column (GE LifeSciences), followed by washing and elution 
with 20 and 200 mM imidazole, respectively, using an ATKA Pure FPLC (GE Healthcare).  
Fractions containing TPP1 were concentrated and exchanged into buffer (25 mM Tris pH 8.0, 150 
mM NaCl, 5 mM DTT) using a Centricon-10 device (Amicon). The sample was incubated with 
SUMO (Ulp1) protease (Invitrogen) overnight at 4oC with gentle mixing by rotation at 20 r.p.m. 
to cleave the tag.  Samples were then loaded on a HiLoad 16/600 Superdex 200 column (GE 
Healthcare).  Eluted fractions containing TPP1 were collected and pooled. Protein concentration 
was determined by Bradford Assay (BioRad) and purity was determined by SDS–PAGE and 
Coomassie staining.  
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3.1.8 Expression and purification of tcTERT 
tcTERT was expressed and purified as described previously with some modifications 32 144. 
An Epiphyte3 LEX bioreactor was used to grow tcTERT in BL-21(DE3) pLysS cells at 37 °C until 
they reached an OD600 of 0.6-0.8, after which we induced protein expression with 1 mM Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and dropped the temperature to 30 °C for 4-5 hours of protein 
induction. Cells were harvested via centrifugation at 4000 x g until lysis. For tcTERT purification, 
we used buffers containing 0.75 M KCl and 10% glycerol for the initial purification step on Ni-
NTA columns (GE Healthcare). Samples were further purified via cation exchange on a POROS 
HS column (Thermo Fisher), using a salt gradient of 0.5 M KCl to 1.5 M KCl. Next, the 
hexahistidine tag was cleaved with Tobacco etch virus (TEV) protease overnight at 4 °C. The cut 
tag and TEV protease were separated from the protein with an additional Ni-NTA column 
chromatography step. The final chromatography step was a Sephacryl S-200 16/60, GE Healthcare 
column using a buffer containing 50 mM Tris-HCl, pH 7.5, 10% glycerol, 0.8 M KCl and 1 mM 
Tris(2-carboxyethyl)phosphine (TCEP). Resultant tcTERT was concentrated down to 18 mg mL-
1 and stored at 4°C 32.  
3.1.9 Pre-steady-state kinetics of tcTERT inserting 6-thio-dGTP 
Pre-steady-state kinetic parameters of tcTERT were obtained using established pre-steady-
state kinetics protocols for DNA polymerases, also known as single turnover kinetics145,146. 
Briefly, we preincubated 2 μM tcTERT with 200 nM annealed DNA:RNA hybrid substrate, with 
a 6-FAM label on the 5’ end of the DNA component. We then used a KinTek RQF-3 (a rapid 
quench-flow instrument) to mix equal ratios of the incoming nucleotide triphosphate and 10 mM 
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MgCl2 with the existing mix of tcTERT and its DNA:RNA hybrid substrate. Reactions were run 
at 37°C and quenched at various timepoints with 100 mM EDTA pH 7.5. In each case, the 
conditions used for each reaction were: 25 mM TRIS pH 7.5, 0.05 mg mL-1 Bovine Serum 
Albumin, 1 mM dithiothreitol, 10% glycerol, 200 mM KCl, 1 μM tcTERT, 100 nM annealed 
DNA:RNA hybrid substrate, and varying concentrations of 6-thio-dGTP. After each reaction, the 
samples were transferred to a DNA gel loading buffer, containing 100 mM EDTA, 80% deionized 
formamide, 0.25 mg ml−1 bromophenol blue and 0.25 mg ml−1 xylene cyanol. These mixes were 
then incubated at 95°C for 5 mins, and loaded onto a 21% denaturing polyacrylamide gel. These 
gels were run at 700 V, 60 A, and 30 W at 30°C in order to separate the reaction product from its 
substrate.  
 
Gels were scanned and imaged using a GE Typhoon FLA 9500 imager, and the ratios of 
product to substrate were quantified using ImageJ 147. Means and standard deviations were taken 
from at least three replicates were calculated, and graphed using KaleidaGraph. Plots of product 
formation over time were fit to the exponential Equation 1 to determine kobs values: 
[P] = A(1 − e−kobs𝑡) 
In which [P] is the concentration of the product, A is the target engagement (amplitude), 
and t is the reaction time. After kobs values were determined for multiple nucleotide triphosphate 
concentrations, the data was replot to compare kobs to concentration of nucleotide triphosphate, 
and fit to Equation 2: 




With kpol representing the theoretical maximum value of kobs, and [NTP] representing the 
concentration of the nucleotide of interest. 
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3.1.10 Polymerase  dGTP run-on assay 
40 nM polymerase , 400 nM primer-template DNA with a 5’ 6-FAM labeled primer, were 
preincubated for 20 minutes. We then used a multi-channel pipette to mix equal ratios of the 
incoming nucleotide with 1 mM MgCl2 to start the reaction. Reactions were run at 37°C in a 
LabDoctor™ heating and quenching was accomplished using a solution of DNA gel loading 
buffer. In each reaction the conditions were: 50 mM TRIS pH 7.5, 0.1 mg/mL Bovine Serum 
Albumin, 1 mM dithiothreitol, 10% glycerol, 100 mM KCl, 20 nM polymerase , 200 nM primer 
template DNA and either 50 μM or 200 μM dGTP or dTTP. These mixes were then incubated at 
95°C for 5 mins, and loaded onto a 21% denaturing polyacrylamide gel. These gels were run at 
700 V, 60 A, and 30 W at 30°C in order to separate the reaction product from its substrate. Gels 
were scanned and imaged using a GE Typhoon FLA 9500 imager. 
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4.0 Results 
4.1 Modified dNTPs decrease telomerase processivity 
 To determine if telomerase can utilize oxidatively damaged 2-OH-dATP and 8-oxo-dATP 
or therapeutic NRTIs and 6-thio-dGTP (Figure 8) for telomere elongation, we conducted direct 
telomeric repeat addition assays. For NRTIs we selected didanosine (ddITP) and azidothymidine 
(AZT-TP) based on evidence they promote telomere shortening 118,119,123.The telomerase catalytic 
cycle starts when the telomeric single strand overhang base pairs with the complementary 3’ end 
of the telomerase RNA template priming DNA synthesis 43.  Upon incorporation of the incoming 
dNTP, the telomerase active site moves to the next template base and telomere elongation 
continues until the template 5’ boundary is reached for processive nucleotide addition (Figure 4, 
steps 2-3). In human telomerase, the template region is 11 nt (3′-rCAAUCCCAAUC-5′)  
comprising of an alignment region plus a template sequence, GGTTAG (numbered 1-6 in Figure 
4). Then, telomerase can either dissociate or translocate on the DNA product, generating a 
realigned 5-bp RNA:DNA hybrid for processive repeat addition. The 6-nt RNA template is reverse 
transcribed for each cycle of repeat addition and template recycling (Figure 4, steps 2-4). 
Nucleotide addition processivity (NAP) is the number of nucleotides added prior to enzyme 
dissociation from the template, and repeat addition processivity (RAP) is the number of repeats 




For telomerase reactions, we used the standard substrate of three TTAGGG repeats and 
immunopurified FLAG-tagged telomerase overexpressed in human HEK 293T cells. This enzyme 
preparation, termed super telomerase, has kinetic properties similar to endogenous telomerase 
(Figure 9)36,148,149.   We conducted the reactions with cellular relevant dNTP concentrations (24 
μM dATP, 29 μM dCTP, 37 μM dTTP, 5.2 μM dGTP, averaged from multiple studies150)  since 
dNTP pool balance can impact telomeric DNA synthesis150.  We replaced increasing 
Figure 8.  dNTPs used in telomerase reactions. (Chemical structures of dNTP analogs used in this study and 
the corresponding natural dNTP shown in the same color. 
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concentrations of the natural dNTP with the corresponding oxidized or therapeutic dNTP analog 
(0.5 μM -125 μM) in reactions containing the remaining three natural dNTPs (Figure 10).  Repeat 
processivity was measured using the convention of calculating the number of repeats synthesized 
before half of the DNA substrates dissociate from telomerase15 (Supplementary Fig. 2). 8-oxo-
dGTP served as a control since it is an established telomerase chain terminator91.  As expected, 
increasing dGTP, dATP or dTTP amounts greatly increased processivity as evidenced by the 
appearance of longer products (Figure 11).  Loss of signal at the highest dGTP concentration was 
due to dGTP competing with the low radioactive dTTP amounts used to label the products, and 
was not observed in dATP or dTTP titration reactions containing radio-labeled dGTP (Figure 11 
and Figure 10).  Similar to 8-oxo-dGTP, 8-oxo-dATP failed to support processive elongation 
(Figure 11, a and b). In contrast, we observed moderate telomeric synthesis in the presence of 2-
OH-dATP, but processivity was lower than control reactions containing the unmodified dATP 
(Figure 11b and Figure 10).  These data indicate that oxidatively damaged dATPs inhibit 
telomerase, although to a different extent depending on the type of modification.   
 
Next, we examined whether telomerase could utilize therapeutic dNTPs for telomere 
elongation. Reactions with 6-thio-dGTP showed only one repeat added, although at the highest 6-
thio-dGTP concentrations telomerase incorporated two additional nucleotides after translocation 
at the rC1rC2 template positions, but not beyond  (Figure 11a, lanes 7 and 8). This suggests 6-
thio-dGTP inhibits both nucleotide and repeat processivity. Although the NRTI didanosine is an 
adenine analog, when taken orally, it is converted to either ddATP or ddITP, which is an 
isoguanine151,152. When ddITP replaced dGTP in the reaction, we observed no synthesis past the 
first rC6 template even with increasing ddITP concentrations (Figure 11a, lanes 9 and 10). 
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Virtually no products were observed in reactions containing AZT-TP, although incorporation 
opposite the first rA3 template blocks further extension (Figure 11c).  In summary, the aborted 
extension products show substitution of the natural dNTPs with 8-oxo-dNTPs inhibit telomerase 
activity to a similar extent as substitution with NRTI HIV-RT chain terminators or 6-thio-dGTP.  
Our data suggest that either telomerase cannot incorporate these modified dNTPs during telomeric 




Figure 9. Quantification of immunopurified telomerase-protein-RNA complexes. (a) Telomerase was 
over expressed in HEK293T cells and immunopurified (IP) using a FLAG tag on the N-terminus of 
TERT. The beads or eluate from IP reactions were spotted on a blot and probed with a 32P labeled probe 
against hTR to determine the concentrations of RNA that co-purified with TERT. 1, 2.5, and 5 μL 
aliquots were compared with in vitro transcribed hTR standards from 0.5 to 250 fmol.  Concentrations 
are shown. (b) Standard curve of hTR standards to determine concentration of telomerase. (c) 
Telomerase primer extension assays. Telomerase activity from beads and eluent preparations were 










Figure 10. Modified dNTP titration gels and processivity calculations Telomerase reactions were conducted with 
(TTAGGG)3 primer 1 and cellular-concentration dNTPs (24 μM dATP, 29 μM dCTP, 37 μM dTTP, 5.2 μM 
dGTP) except that the indicated natural or modified dNTP was added at increasing concentrations (0, 0.5, 1, 5, 
25, and 125 μM) along with either 0.3 μM [α-32P]dTTP (a) or [α-32P] dGTP (b, c). The loading control (LC) was a 
32P-end labeled 18-mer. Numbers on the left indicate the number of added repeats. (d) Processivity was calculated 
as R1/2 (see Methods). (e) The natural log of (100-%LB) was plotted vs repeat number. A straight line was fit to 
the data and the R1/2 was calculated by dividing –ln(2) by the slope of each line. Plots shown from one experiment.  





Figure 11.  Oxidized and therapeutic dNTPs inhibit telomerase processivity. Telomerase reactions were conducted with 
(TTAGGG)3 primer (3R) and cellular-concentration dNTPs (24 μM dATP, 29 μM dCTP, 37 μM dTTP, 5.2 μM dGTP) except 
that the indicated natural or modified dNTP was titrated in at increasing concentrations (0, 5, 125 μM) along with either 0.3 
μM [α-32P]dTTP (a) or 0.3 μM [α-32P]dGTP (b, c) to label the products. The loading control (*) was a 32P-end labeled 18-mer 
oligonucleotide. Numbers on the left indicate the number of added repeats; letters on the right indicate template residue. 
Images are representative of three independent experiments. 
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4.2 Telomerase inhibition mechanism depends on the modified dNTP 
A chain terminating mechanism of inhibition requires that the enzyme adds the modified 
dNTP to a growing chain, which then blocks further synthesis.  Since we showed previously that 
8-oxo-dGTP is a genuine telomerase chain terminator, we used it here as a positive control91. To 
test whether telomerase can incorporate other modified dNTPs, and whether the incorporation is 
chain terminating and/or mutagenic, we conducted a direct telomerase extension assay in which 
we radiolabeled the primer and added increasing concentrations (5, 50, and 500 μM) of only a 
single dNTP (Figure 14, Figure 15, and Figure 16). Since modified dNTPs may prefer 
mispairing, we tested various primers in which the first template base was either rA3, rC1, or rU5 
(primer 1, primer 2, and primer 3, respectively), and compared the percent primer extension for 
each dNTP at the middle 50 M concentration (Figure 17).  Primers 1 and 2 initiate synthesis at 
consecutive rA3rA4 or rC1rC2 template bases, respectively, so we could examine both 
incorporation and extension to the next base. However, the telomerase template lacks tandem rU 
residues.   
We first tested incorporation of natural dNTPs at the various template positions as controls.  
Reactions with a single dNTP type is an established method for determining DNA synthesis 
fidelity, defined as selectivity for incorporating a correct dNTP versus an incorrect or modified 
dNTP153,154. Interestingly, telomerase extended all three primers in the presence of dGTP, 
indicating telomerase can incorporate dGTP opposite each template base even at low cellular 
concentrations (5 M) (Figure 12).  However, comparisons at 50 M dGTP indicates a preference 
for correct incorporation over misincorporation in order of rC1 (33%, primer 2) > rA3 (19%, primer 
1) > rU5 (4%, primer 3) extension (Figure 17 lanes 2).  We also observed telomerase synthesis of 
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poly-dG ladders, as reported previously91, even at early time points and synthesis at a single rC 
(Figure 13 a and b).  As a control, reactions with DNA polymerase  showed no evidence of 
dGTP laddering or misincorporation opposite template A (Figure 13c and d).  Poly-nucleotide 
ladders were not observed in reactions with any other dNTP (Figure 17) or with RNase addition  
(Figure 9). In the presence of dTTP, telomerase preferentially extended primer 1, showing 
incorporation opposite rA3 and strong termination after rA4, as expected, but also minor extension 
to the subsequent rU5 (Figure 17a lanes 3, and Figure 14).  Consistent with this, telomerase could 
extend primer 3 by misincorporating dTTP opposite rU5 (Figure 17c lane 3).  Thus, while 
telomerase can misinsert dTTP, it strongly prefers correct insertion (41% primer 1 extension versus 
9% primer 3 extension). Similarly, telomerase strongly preferred correct insertion of dATP 
opposite rU5, elongating primer 3 with minimal extension to the next rC1, and poor or no extension 
of primers 1 and 2, respectively (Figure 17 lane 4).  Finally, telomerase only extended primer 1 
in the presence of dCTP, indicating some misincorporation opposite rA3 (Figure 17 lane 5, Figure 
14).  In summary, these experiments show that telomerase extension was most accurate with 
primer 2 (template rC1) and least accurate with primer 1 (template rA3).  Additionally, telomerase 
incorporation of dGTP is more error prone than the other natural dNTPs, as indicated by the 
production of poly d(G) ladders.    
We next tested whether telomerase can incorporate oxidized dATPs onto the growing 
telomere chain using the end-labeled primers.  Telomerase elongated primer 1 by misinserting 8-
oxo-dGTP opposite rA3 with minimal extension to the next template rA4, confirming its chain 
terminating ability (Figure 17 lanes 6 and Figure 15)91. Telomerase showed little to no extension 
of primers 2 and 3 with 8-oxo-dGTP, indicating poor incorporation opposite rC1 or rU5.  In 
contrast, we detected virtually no extension of any primers with 8-oxo-dATP, except for minimal 
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misinsertion opposite rA3 with primer 1 (Figure 17 lanes 7 and Figure 15), suggesting 8-oxo-
dATP is a very poor substrate for telomerase. However, telomerase readily extended primer 3 by 
inserting inserting 2-OH-dATP opposite the correct rU5, generating only 2-fold less product than 
with dATP (16% versus 30%, respectively), and showed minimal extension to the next incorrect 
rC1 position (Figure 17 lanes 8). Unlike 8-oxo-dGTP, telomerase insertion of 2-OH-dATP is not 
mutagenic, showing very low extension of primers 1 and 2 indicative of poor misinsertion opposite 
rA3 and rC1, respectively.  The single template rU did not allow us to determine whether 2-OH-
dATP insertion is chain terminating. In summary, our data indicate telomerase insertion of 
oxidized dNTPs follows the order 2-OH-dATP > 8-oxo-dGTP > 8-oxo-dATP opposite their 
preferred template base.   
Analysis of the therapeutic dNTPs demonstrates that telomerase is able to add each of these 
analogs to a telomere chain Regarding the NRTIs, telomerase inserted ddITP opposite rC1, 
extending primer 2 with moderate efficiency (16% extension) compared to reactions with dGTP 
(33% extension), but did not extend to the next rC2 (Figure 17 lanes 10 and Figure 16).  
Telomerase extended primer 1 with AZT-TP, showing correct insertion opposite rA3 with no 
extension to the next rA4; yielding 26% extension compared to 41% extension with dTTP (Figure 
17 lanes 11).  These data definitively show that these HIV-1  RT chain terminators are also genuine 
telomerase chain terminators, and define the inhibition mechanism.  Strikingly, telomerase was 
able to extend all three primers with 6-thio-dGTP, showing a preference for incorporation in order 
of template rC1 (45%) > rA3 (13%) > rU6 (4%) primer extension ( Figure 17 lanes 9), at product 
yields comparable to dGTP incorporation. In reactions with primer 2, telomerase correctly 
incorporated 6-thio-dGTP opposite rC1, showing strong termination after insertion opposite the 
next rC2. This suggests that, like dGTP, 6-thio-dGTP can bind at the telomerase active site at all 
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template primer positions, however unlike dGTP, it does not support poly-nucleotide laddering. 
Our data indicate telomerase insertion of therapeutic dNTPs follows the order 6-thio-dGTP > AZT-
TP > ddITP. Unlike the NRTIs and 8-oxo-dGTP, 6-thio-dGTP is not a telomerase chain terminator, 
















Figure 12. Telomerase extension with dGTP. Direct telomerase assays were conducted with 5 nM 32P-end labeled primer (a)  
Primer 1 (TTAGGG)3, (b) Primer 2 (GGTTAG)3, or (c and d) Primer 3 (AGGGTT)3.  Reactions contained cellular-
concentration dNTPs (24 μM dATP, 29 μM dCTP, 37 μM dTTP, 5.2 μM dGTP ) (all) or 5, 50, or 500 µM dGTP. In panel 
(d) reactions contained 3 µg/µl RNase A. Products were separated on denaturing gels. Letters on the right indicate the 
template base; P indicates unextended primer. Graphs represent the percent of total primers extended for the reactions in 
panels a – c from one experiment.   
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Figure 13. Time course reactions with telomerase or pol β. (a, b) Telomerase reactions were 
conducted with 5 nM 32P-end labeled primer (a) Primer 4 (GTTAGG)3 or (b) Primer 2 (GGTTAG)3. 
Reactions contained 50 μM dGTP and were terminated at 0, 1, 3, 5, 9, 15, 30, or 45 minutes as 
indicated. Products were separated on denaturing gels. Letters on the right indicate the template 
base; P indicates unextended primer. Graphs represent the percent primer extended for the 
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reactions in panels a and b from one experiment. (c, d) Primer extension by human polymerase .  
The double stranded 6-FAM labeled primer-template and polymerase  were incubated with either 
50 µM dGTP or dTTP (c), or 200 µM dGTP or dTTP (d) for time ranging from 8-240 minutes as 
indicated. The products of the reactions were run on denaturing gels and the gels were imaged 








Figure 14. Telomerase extension with natural dNTPs. Direct telomerase assays were conducted with 5 nM 32P-end labeled 
primer (a)  Primer 1 (TTAGGG)3, (the box around dTTP reactions indicates image from a separate gel) (b) Primer 2 
(GGTTAG)3, or (c) Primer 3 (AGGGTT)3. Reactions contained 5, 50, and 500 µM dTTP, dATP, or dCTP as indicated. 
Products were separated on denaturing gels. Letters on the right indicate the template base; P indicates unextended primer. 





Figure 15. Telomerase extension with oxidized dNTPs. Direct telomerase assays were conducted with 5 nM 32P-end labeled 
primer (a)  Primer 1 (TTAGGG)3, (b) Primer 2 (GGTTAG)3, or (c) Primer 3 (AGGGTT)3. Reactions contained 5, 50, and 500 
µM 8-oxo-dGTP (8dG), 8-oxo-dATP (8dA), or 2-OH-dATP (2dA) as indicated. Products were separated on denaturing gels. 
Letters on the right indicate the template base; P indicates unextended primer. Graphs represent the percent of total primers 




Figure 16. Telomerase extension with therapeutic dNTPs. Direct telomerase assays were conducted with 5 nM 32P-end 
labeled primer (a) Primer 1 (TTAGGG)3, (b) Primer 2 (GGTTAG)3, or (c) Primer 3 (AGGGTT)3. Reactions contained 5, 
50, and 500uM 6dG (6-thio-dGTP), ddI (ddITP) or ZdT (AZT-TP) as indicated. Products were separated on denaturing 
gels. Letters on the right indicate the template base; P indicates unextended primer. Graphs represent the percent of total 















Figure 17. Telomerase insertion of modified dNTPs. Telomerase reactions were conducted with 5 nM 32P-end 
labeled primer (a) Primer 1 (TTAGGG)3, (b) Primer 2 (GGTTAG)3, or (c) Primer 3 (AGGGTT)3. Reactions 
contained cellular-concentration dNTPs (24 μM dATP, 29 μM dCTP, 37 μM dTTP, 5.2 μM dGTP) (lane 1) or 50 
μM of indicated natural dNTP (blue, lanes 2-5), oxidized dNTP (red, lanes 6-8), or therapeutic dNTP (green, lanes 
9-11). Products were separated on denaturing gels. 8dG (8-oxo-dGTP); 8dA (8-oxo-dATP); 2dA (2-OH-dATP); 6dG 
(6-thio-dGTP); ddI (ddITP); ZdT (AZT-TP).  Letters on the right indicate the template base; P indicates 
unextended primer. Graphs represent the percent of total primers extended. Data are shown as mean + s.d. from 
three independent experiments.. 
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4.3 2-OH-dATP and 6-thio-dGTP insertion disrupt telomerase translocation 
To better understand how 2-OH-dATP and 6-thio-dGTP inhibit the telomerase catalytic 
cycle, we examined whether telomerase could incorporate a natural dNTP after adding the 
modified dNTP. First, we used primer 3 to examine extension after insertion opposite rU5 in 
reactions with 50 M each of dTTP, dGTP and either dATP or 2-OH-dATP.  We observed typical 
processive synthesis with all three natural dNTPs, but replacing dATP with 2-OH-dATP generated 
a strong termination product after extension to the next base (rC6), which is the final base prior to 
translocation (Figure 18a).  These data indicate that telomerase can extend after insertion of 2-
OH-dATP, but translocation to add the next repeat is greatly compromised.  Those few reactions 
that continued after translocation terminated prior to reaching the template end, suggesting 2-OH-
dATP disrupts both repeat and nucleotide processivity. Next, we conducted reactions with 50 M 
each of dATP, dTTP and either dGTP or 6-thio-dGTP. Figure 18b-d show typical processive 
synthesis with the natural dNTP after initiating synthesis opposite rA3 (primer 1), rC1 (primer 2), 
and rU5 (primer 3). Next we replaced dGTP with 6-thio-dGTP.  Primer 1 reactions show strong 
termination products after telomerase inserted 6-thio-dGTP opposite rC6 position (4 nucleotides 
added)  (Figure 18b), suggesting dissociation prior to translocation We also observed strong 
termination products at the next rC1 (5 nucleotides added), indicating either successful 
translocation in some reactions followed by dissociation, or template slippage for an additional 6-
thio-dGTP incorporation prior to translocation. This result was recapitulated with primer 3.   
Figure 18 shows that after telomerase inserted dATP opposite rU5, the majority of the reactions 
terminated after 6-thio-dGTP insertion opposite rC6 or the next rC1.  Finally, reactions with primer 
2 show that telomerase incorporates 6-thio-dGTP opposite the first two rC1rC2 positions, but 
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primarily terminates synthesis after extension to rA3 (three nucleotides added) prior to 
translocation, despite the availability of natural dNTPs to add another repeat (Fig. 4c).  Telomerase 
can also add a natural nucleotide (dTTP opposite rA) after 6-thio-dGTP insertion, confirming 6-
thio-dGTP is not a chain terminator.  However, termination prior to completing synthesis of the 6-
nt repeat indicates that 6-thio-dGTP not only disrupts repeat processivity, but also nucleotide 
processivity. Our data suggest 6-thio-dGTP and 2-OH-dATP addition interfere with telomerase 
















Figure 18. 2-OH-dATP and 6-thio-dGTP insertion disrupt telomerase translocation. Direct telomerase assays 
were conducted with 5 nM 32P-end labeled primer (a and d) Primer 3 (AGGGTT)3, (b) Primer 1 (TTAGGG)3 or 
(c) Primer 2 (AGGGTT)3. Reactions contained 50 μM dATP, dTTP and dGTP, except when 2-OH-dATP (2dA) 
or 6-thio-dGTP (6dG) was substituted for dATP or dGTP, respectively where indicated. Products were separated 
on denaturing gels. Letters on the right of the graph indicate the template base; P indicates unextended primer. 
Graphs represent percent of product terminated at each template position as a function of total products. Data 
are the mean + s.d. from three independent experiments. 
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4.4 POT1-TPP1 fail to restore telomerase processivity inhibition  
Next we tested whether the telomerase processivity factor POT1-TPP1 could modulate 
modified dNTP inhibition of telomerase.  POT1 binds to the telomeric ssDNA overhang, requiring 
the minimum ssDNA sequence of 5’-TTAGGGTTAG-3’155.  The inclusion of POT1 binding 
partner TPP1, increases the binding affinity for telomeric DNA ten-fold compared to POT1 
alone156. POT1-TPP1 recruits telomerase to telomeres in vivo156, and greatly increases telomerase 
processivity15. Therefore, we reasoned that POT1-TPP1 may be able to overcome inhibition by the 
modified dNTPs and enhance telomerase processivity. We conducted telomerase extension 
reactions with radiolabeled primer in the presence of purified POT1-TPP1, and used a primer with 
a single mutation (TTAGGGTTAGCGTTAGGG; underlined G to C mutation)55 to ensure the 
POT1-TPP1 would be positioned at the 5’ portion of the DNA primer (Figure 19). This provides 
a homogenous substrate for telomerase extension.  
For these reactions, we replaced the natural dNTP with the modified dNTP analog, while 
the other dNTPs remained at cellular relevant concentrations. As a positive control, we show the 
addition of POT1-TPP1 to telomerase reactions containing all natural dNTPs significantly 
increased repeat processivity (R1/2) from 2.5 to 4.5, as indicated by the appearance of longer 
products (Figure 19 a lanes 1 and 2, and 5c).   R1/2 represents the number of repeats added before 
half of the DNA substrates dissociate from telomerase, meaning nearly half of the bound primers 
were elongated by roughly 5 repeats in the presence of POT1-TPP1. When dGTP was replaced 
with 8-oxo-dGTP, addition of POT1-TPP1 was unable to overcome the chain termination (Figure 
19a lanes 3 and 4).  In contrast, for reactions in which 2-OH-dATP replaced dATP, POT1-TPP1 
stimulated telomerase extension by enhancing processivity 5-fold from 0.5 to 2.3 (Figure 19a 
lanes 7 and 8, and 5c).  This suggests that 2-OH-dATP incorporation may disrupt telomerase 
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interaction with the primer, which may be partly compensated for by POT1-TPP1. For reactions 
in which dATP was replaced with 8-oxo-dATP, we observed some POT1-TPP1 stimulation, 
although processivity was still greatly reduced compared to reactions with all natural dNTPs 
(Figure 19a lanes 5 and 6).  However, we suspect this synthesis may have resulted from 
misincorporation of dGTP or dTTP opposite rU in the absence of dATP (Figure 17c lanes 2 and 
3), since 8-oxo-dATP is a poor substrate for telomerase. As expected, POT1-TPP1 failed to 
stimulate telomerase processivity in reactions containing ddITP and AZT-TP, since insertion of 
ddITP opposite rC and AZT-TP opposite rA halted further synthesis (Figure 19b lanes 5-8).  
However, POT1-TPP1 also failed to stimulate telomerase when dGTP was replaced with 6-thio-
dGTP (Figure 19c lanes 3 and 4), indicating this analog is also a strong telomerase inhibitor.  
Overall, these data indicate that POT1-TPP1 is not able to fully restore telomerase extension in the 
presence inhibitory dNTPs, although these proteins can partly stimulate processivity in reactions 













Figure 19. POT1-TPP1 fail to overcome inhibitory dNTPs. Direct telomerase assays were conducted in the absence or presence 
of 500 nM POT1 and 500 nM TPP1, as indicated, and 5 nM 32P-end labeled primer (TTAGGGTTAGCGTTAGGG) designed 
to position POT1 at the 10 nt primer 5’ end. Reactions contained cellular-concentration dNTPs (24 μM dATP, 29 μM dCTP, 37 
μM dTTP, 5.2 μM dGTP) (lanes 1 and 2), except when the natural dNTP was substituted with the oxidized dNTP (a) or 
therapeutic dNTP (b) analog (lanes 3-8), as indicated.  8dG (8-oxo-dGTP); 8dA (8-oxo-dATP); 2dA (2-OH-dATP); 6dG (6-thio-
dGTP); ddI (ddITP); ZdT (AZT-TP). Letters on the left indicate template base; P indicates unextended primer. (c) Processivity 
calculated on the basis of total products normalized to loading control. Data are shown as mean + standard deviation from 
three independent experiments. 
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4.5 Telomerase exhibits poor selectivity against 6-thio-dGTP, ddITP and 2-OH-dATP 
In order to gain further insight into the ability of modified dNTPs to compete with natural 
dNTPs for telomerase utilization, we added modified dNTPs to reactions containing all four 
natural dNTPs.   We conducted reactions with cellular relevant concentrations of natural dNTPs 
and titrated the modified dNTP from 0 to 10,000 μM to calculate the half maximal inhibitory 
concentration (IC50) based on telomerase repeat processivity (Figure 20).  The calculated IC50 
determines the concentration required to reduce repeat processivity in the bulk reactions by half.  
However, it is important to note that bulk experiments cannot distinguish effects on individual 
telomeres, since extended telomeres mask unextended telomeres. Incorporation of a chain 
terminator during any step will terminate extension of the affected telomere, and just five critically 
short telomeres are sufficient to trigger senescence157. Therefore, repeat processivity IC50 values 
are not necessarily an indicator of the inhibitory potency, but provide information on selectivity 
for modified dNTPs compared to natural dNTPs. The oxidized dNTPs 8-oxo-dATP and 8-oxo-
dGTP had similar IC50 values as the genuine chain terminator AZT-TP ranging from 402 to 1690 
M (Table 2). However, the therapeutic dNTPs 6-thio-dGTP and ddITP, and oxidized 2-OH-
dATP, displayed the lowest IC50 values of 5, 61, and 103 μM, respectively. Our data suggest these 
modified dNTPs, especially 6-thio-dGTP, can effectively compete with the natural dNTPs for 
binding in the telomerase active site.  Given the remarkably low IC50 for 6-thio-dGTP, we 
examined the catalytic efficiency of 6-thio-dGTP incorporation versus dGTP using the Tribolium 
castaneum (tcTERT) model of the telomerase catalytic core32.  The ability to purify sufficient 
quantities of tcTERT enables characterization of the catalytic nucleotide addition by pre-steady-
state single turnover kinetics using a defined DNA-RNA primer-template substrate144. The 
catalytic efficiency of incorporating a single dNTP is measured by dividing the observed 
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nucleotide incorporation rate constant, kpol, by the equilibrium dissociation constant for dNTP 
binding to the tcTERT-primer-template complex (Kd) 158. The catalytic efficiency of inserting 
dGTP is only 2-fold higher at 0.034 M-1s-1 compared to 6-thio-dGTP at 0.056 M-1s-1, indicating 
poor selectivity against this dNTP analog (Table 3).  Collectively, these results indicate that 
modified dNTPs vary in the ability to compete with the natural dNTPs for utilization by 
telomerase.    











Table 3. Single-turnover kinetic values for tcTERT single nucleotide insertion 




dGTPa 1.1 + 0.03 18.1 + 3.78 0.058 + 0.012 1.000 
6-thio-dGTP 3.1 + 0.23 92.4 + 12.94 0.034 + 0.005 0.579 
 
aValues from 144. 
Modified dNTP IC50 μM + SD 
8-oxo-dATP 946 + 49 
2-OH-dATP 103+ 66 
8-oxo-dGTP 1690 + 172 
ddITP 61 + 23 
AZT-TP 402 + 169 
6-thio-dGTP 5 + 2 
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Figure 20. IC50 values for telomerase processivity inhibition. Telomerase reactions were conducted with cellular relevant 
concentrations of all four natural dNTPs and increasing concentrations of the modified dNTP analog from 0 to 10,000 μM 
to calculate (a) the processivity as R1/2 and (b) the half maximal inhibitory concentration (IC50) based on telomerase 
processivity. Means and s.d. are from 3-4 independent experiments, and from 2 experiments for the ddITP reactions.. 
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Figure 21. Representative titration gels for IC50 values. Telomerase reactions were conducted with cellular relevant 
concentrations of all four natural dNTPs and increasing concentrations of the modified dNTP analog from 0 to 10,000 μM. 
Products were separated on denaturing gels; P indicates unextended 18-mer primer. Images are representative from 3-4 
independent experiments, and from 2 experiments for AZT-TP reactions. 
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5.0 Discussion 
Previous studies showed that treatments with NRTIs and thiopurines, or the failure to 
remove oxidized dNTPs, drive telomere shortening in human cells.  Here, we report two distinct 
mechanisms by which oxidized and therapeutic dNTPs inhibit telomerase mediated telomere 
elongation, either by chain termination or by disrupting translocation and subsequent repeat 
addition. By using end labeled telomeric primers, we provide direct evidence that telomerase can 
add the HIV RT inhibitors ddITP and AZT-P to a growing telomere chain, and that incorporation 
halts further elongation. Unlike the NRTIs and 8-oxo-dGTP, we found that telomerase could 
continue elongation after inserting a 2-OH-dATP and 6-thio-dGTP, but that addition of these 
modified dNTPs strongly inhibits repeat addition processivity (RAP), leading to truncated 
products. We propose a mechanism by which insertion of these RAP inhibitors disrupt stable 
formation of the RNA:DNA hybrid required for successful translocation and continued repeat 
addition.  
Defining the mechanism of telomerase inhibition requires analysis of whether telomerase 
can catalyze the addition of the modified dNTP to the telomeric end.  Reactions with a single dNTP 
type also inform about selectivity for inserting a correct dNTP versus an incorrect or modified 
dNTP during DNA synthesis158.  Control reactions with natural dNTPs at different template 
positions revealed several aspects of telomerase fidelity of DNA synthesis.  First, we found that 
telomerase incorporation of dGTP is more error prone than the other natural dNTPs, as indicated 
by dGTP misincorporation opposite rA and rU even at low 5 M and the production of poly d(G) 
ladders. This propensity for telomerase to misinsert dGTP competes with insertion of the low 
radioactive dTTP amounts used to label the products in Fig. 2a, explaining the loss of radiolabeled 
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products at high dGTP concentrations. In contrast, high dATP or dTTP concentrations did not 
outcompete insertion of radiolabeled dGTP in Fig. 2b and c. However, we observed some dTTP 
misincorporation opposite template rU even at low 5 M, and propose that misinsertion of dGTP 
and dTTP opposite rU likely explains the one repeat addition observed when dATP is absent (Fig. 
2b lane 2).  For reactions containing only dGTP, the poly d(G) ladders appeared at early time 
points and low percent primer extension (<10%) suggesting they resulted from processive 
nucleotide addition. Previous reports have also shown that both human and ciliate telomerase can 
make poly d(G) ladders, and suggest this is due to DNA hairpin-induced slippage of the telomerase 
product 3’ end relative to the template C tract 159,160. In addition, high dGTP concentrations 
overcome the template embedded pause site that slows addition of the first dGTP for GGTTAG 
repeat synthesis161. Telomerase has a lower Km for dGTP incorporation than other dNTPs, which 
suggests that telomerase has increased dGTP binding affinity23,154,162, and may explain the higher 
propensity for dGTP misinsertion and poly d(G) synthesis.   
The oxidative stress-induced telomere shortening and loss observed upon MTH1 inhibition 
has been attributed to telomerase incorporation of 8-oxodGTP which prevents further elongation91.  
Our biochemical results that oxidized dATPs inhibit telomerase indicate that they can also 
contribute to telomerase inhibition in MTH1 depleted cells.  However, unlike 8-oxo-dGTP, 8-oxo-
dATP is very poor substrate for telomerase.  DNA synthesis accuracy depends on discrimination 
against base pairs that cannot adopt Watson-Crick like geometry.  While polymerase studies of 8-
oxo-dATP insertion are lacking, studies with 8-oxodA in the template show mammalian DNA 
polymerases insert dTTP or dGTP opposite 8-oxodA and accommodate the base pair partly 
through base tautomerization and interactions with polymerase residues at the active site163. 
Telomerase may lack contacts required to stabilize an 8-oxodA base pair for catalysis. If 8-
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oxodATP occupies the active site in a non-productive manner, it may prevent access to natural 
dNTPs, similar to telomerase inhibitor 5-MeCITP164. Alternatively, 8-oxodATP may interact with 
telomerase elsewhere outside the active site.  In contrast, our data indicate the 2-OH-dATP:rU base 
pair is well tolerated in the telomerase active site, since 2-OH-dATP insertion opposite rU was 
only 2-fold less efficient than dATP. 2-OH-dATP can pair with thymine or uracil either in an enol 
tautomeric form with Watson-Crick hydrogen bonding, or in a  keto form through wobble base 
pairing165,166. Similarly, HIV-1 and avian myeoblastosis virus RTs also preferentially insert 2-OH-
dATP opposite dT or rU, and more efficiently than replicative polymerases  and  167,168. 
Translesion DNA polymerases typically harbor a larger binding pocket to accommodate lesions, 
however, not all TLS polymerases can incorporate 2-OH-dATP. Pol  incorporates 2-OH-dATP 
opposite all template positions except A with an efficiency 2-6% lower than the natural base, 
whereas Pol  cannot incorporate 2-OH-dATP at all169. Our data indicate that telomerase insertion 
of 2-OH-dATP more closely resembles other RTs compared to replicative and TLS polymerases, 
consistent with a similar binding pocket.  
Similar to 2-OH-dATP, we found telomerase readily adds 6-thio-dGTP to the telomeric 
end.  Our data indicate that telomerase exhibits very poor discrimination against 6-thio-dGTP. 
First, dGTP and 6-thio-dGTP yielded similar percent extension of primers initiating synthesis 
opposite the correct rC and the incorrect rA.  Second, although T. castaneum telomerase had lower 
affinity for 6-thio-dGTP, as indicated by a higher Kd than for dGTP, the polymerization rate was 
faster, yielding similar catalytic efficiencies.  Third, 6-thio-dGTP has a very low IC50 for 
telomerase RAP inhibition in bulk biochemical reactions.  This is not surprising given that human 
Pols , ,  and   all insert 6-thio-dGTP with similar efficiencies as dGTP, and structures of Pol 
 inserting 6-thio-dGTP opposite C, versus dGTP, are nearly identical170,171. However, while 6-
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thio-dGTP can support DNA synthesis, it reduces primer elongation by mammalian DNA 
polymerases compared to dGTP170, and strongly inhibits telomerase processivity.  Thus, while the 
sulfur substitution has a minor effect on catalysis, it has a dramatic effect on telomere elongation.  
Our results showing 6-thio-dGTP directly inhibits telomerase processivity, provides an 
explanation for why 6-thio-dG promotes telomere shortening in telomerase positive cells, but not 
telomerase negative cells128.  
Our results demonstrate that 2-OH-dATP and 6-thio-dGTP are not chain terminators, but 
rather inhibit telomerase by disrupting the translocation step.  While insertion of either modified 
dNTP did not prevent extension to the next template base, limited synthesis occurred after the first 
translocation.  About 50% of the reactions terminated after 6-thio-dGTP insertion at the last 
template rC, and the remaining terminated after 6-thio-dGTP insertion at the first template rC 
following translocation, indicating disruption prior to, or immediately following, translocation.  
Translocation involves the separation of the DNA:RNA duplex and repositioning of the DNA 
product to reveal the RNA template and prime additional repeat synthesis. Previous evidence 
suggests the DNA:RNA duplex separation and realignment  occur outside the enzyme active site, 
followed by binding and repositioning the new DNA:RNA hybrid in the active site after 
translocation23,142. Previous work indicates continuous strand separation maintains the DNA-RNA 
hybrid at a consistent length during DNA synthesis, and that 5 bp is optimally accommodated in 
the active site23. Protein interactions in the active site are thought to stabilize this very short hybrid, 
since higher telomerase affinity for the RNA/DNA hybrid correlated with increased RAP. 
Therefore, any perturbations to the 5 bp hybrid stability, either via reduced melting temperature or 
protein interactions, could impact translocation.  While substitution of 6-thio-dG for guanine in a 
dG-dC base pair moderately decreases thermal stability of a 17-mer DNA duplex by 10%, kinetic 
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data indicate the opening rate of a 6-thio-dG-C base pair is 17-fold faster than a dG-dC bp172.  
Structural data indicate that the hydrogen bond is longer with the thio group and dC, compared to 
with the carbonyl group, in the Pol  active site171. Less is known about the impact of 2-OH-dA 
on bp stability, however, alterations in the bp geometry with rU may impact the telomerase affinity 
for the RNA:DNA hybrid. Therefore, we proposed minor perturbations could significantly 
destabilize the already very short thermally unstable 5 bp RNA:DNA, and thereby disrupt 
translocation.  
Results with POT1-TPP1 provide further evidence that 2-OH-dATP and 6-thio-dGTP 
disrupt translocation.  POT1-TPP1 enhance telomerase RAP by decreasing the primer dissociation 
rate and increasing the translocation efficiency55. The result that POT1-TPP1 could partly restore 
RAP in the presence of 2-OH-ATP, suggests that 2-OH-dA increases the rate of primer 
dissociation which is rescued partly by POT1-TPP1 increasing primer binding.  However, POT1-
TPP1 did not increase RAP in the presence of 6-thio-dGTP, suggesting that 6-thio-dG may be 
more destabilizing than 2-OH-dA.  When 6-thio-dGTP replaces dGTP in a reaction, each telomeric 
repeat will contain three 6-thio-dGs, whereas when 2-OH-dATP replaces 2-OH-dA, each repeat 
will contain only one 2-OH-dA.  We argue insertion of three modified dNTPs disrupts the 
DNA:RNA hybrid more than a single dNTP, to such an extent that POT1-TPP1 enhancement of 
telomerase primer binding cannot compensate.   
Here, we demonstrate directly that the NRTIs of ddITP and AZT-TP are human telomerase 
chain terminators by showing the telomerase is able to catalyze the addition of these modified 
dNTPs to the telomeric end.  NRTIs exploit the requirement of DNA polymerases and reverse 
transcriptases for a 3’OH group on the ribose to catalyze addition of the incoming dNTP to the 
growing nucleotide chain. NRTIs lack a 3’-OH found in natural dNTPs and therefore block further 
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elongation after their incorporation into viral DNA, making them efficient inhibitors of HIV-1 RT.  
While several previous reports provide indirect evidence that AZT-P can be incorporated into 
telomeric DNA, reduce telomerase products in vitro, and cause telomere shortening in 
cells118,173,174, our studies provide the first direct evidence that NRTIs are effective telomerase 
chain terminators.  These results have important health implications since the use of AZT has been 
pursued for anticancer treatments as a telomerase inhibitor173. Chronic AZT treatment in mice 
reduced tumor growth and promoted senescence and apoptosis in mammary carcinoma cells126. 
Furthermore, NRTI inhibition of telomerase has been proposed to promote cellular senescence and 
features of premature aging in HIV patients under long term treatments175, and may represent an 
off target effect of NRTIs in human cells. Diminished cellular renewal capacity contributes to the 
underlying cause of premature age related co-morbidities in HIV-infected patients175. 
Since most tumors rely on telomerase to enable cellular immortality, one strategy to halt 
proliferation is to target telomerase with inhibitory nucleosides to prevent telomerase restoration 
of telomeres after each replication. Several recent reports have shown that oral administration of 
6-thio-dG is an effective treatment strategy for melanoma, lung cancer, and glioblastoma in murine 
models135,136,176. These studies also showed that 6-thio-dG treatment led to an increase in telomere 
dysfunction induced foci135,136,176.  Here, we uncover the mechanism by which 6-thio-dGTP 
compromises telomere maintenance via disrupting telomerase translocation. Furthermore, the 
modified nucleotides used in our study not only inhibit telomerase, but reports show they also 
inhibit the mitochondrial DNA polymerase γ, leading to mitochondrial dysfunction and elevated 
ROS which damage dNTP pools120,131. Therefore, in conjunction with MTH1 inhibitors, our 
studies suggest therapeutic NRTIs or thiopurines may deliver a one-two punch to telomerase 
driven cancers by inhibiting telomerase directly and indirectly through elevated oxidized dNTPs.  
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In summary, we show that both naturally oxidized dNTPs and therapeutic dNTPs inhibit 
telomerase activity by distinct mechanisms of either chain termination upon incorporation or 
disruption of telomerase translocation and subsequent repeat addition. Thus, our studies have 
important health implications for potential off target effects on long term NRTI treatments, and 
for therapeutic strategies to target telomerase in cancer (Figure 22). 
 
 
Figure 22. Study model. Treatment with therapeutic dNTPs causes telomerase inhibition which leads to 
telomere dysfunction. Therapeutic dNTPs inhibit polymerase gamma, which elevates ROS and causes 
mitochondrial dysfunction. The elevated ROS can damage dNTP pools and be incorporated into telomeric 
DNA in addition to the therapeutic dNTPs 177. Created with Biorender. 
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6.0 Future directions                   
6.1 6-thio-dGTP at telomeres  
Previous reports have demonstrated that 6-thio-dGTP, which forms in cells from 6-thio-
dG, promotes cell death and telomere shortening in telomerase positive cancer cells. 6-thio-dG 
decreases tumor growth in mouse xenograft studies of lung, glioblastoma, melanoma, and colon 
cancers128.  6-thio-dG treatment causes telomere shortening and telomere dysfunction, but the 
mechanism was unclear because extracts from treated cells do not show reduced telomerase 
activity128. This thesis uncovered the mechanism by which 6-thio-dGTP disrupts translocation 
during repeat addition processivity during the telomerase catalytic cycle. The following section 
will address the next steps of this project, which may answer several remaining questions regarding 
the effects of 6-thio-dG at telomeres.    
6.1.1 Can telomerase bind and then extend the growing chain if 6-thio-dGTP is present in 
the telomeric DNA (primer sequence?)  
We will measure thermodynamic and kinetic binding parameters between telomerase and 
several permutations of the telomeric repeat, as well as rates of nucleotide addition. To determine 
if telomerase can bind to telomeric DNA containing 6-thio-dG, we will measure the equilibrium 
binding constant (Kd) , which is the strength of the binding interaction between the telomeric DNA 
substrates and telomerase. When the Kd value is smaller, it means there is a greater binding affinity 
of the DNA substrate to telomerase, while a higher Kd value means they are more weakly bound.  
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To measure the Kd, we will use a well-established telomerase pull down assay 178. We will use 
biotinylated 18nt telomeric primers with a site specific 6-thio-dG at various locations on the 
primer. We will titrate primers at a range of concentrations and incubate them with 
immunopurified human telomerase as described in section 3.1.1 of this thesis. The DNA substrate 
and any bound telomerase will be captured by Neutravidin beads, and the amount of unbound 
telomerase remaining in the supernatant will be quantified by probing dot blots (as described in 
section 3.1.2 of this thesis) for hTR. The amount of telomerase remaining in the supernatant on 
the blots will be analyzed using Image Quant TL software. Data will be fitted using the following 
equation: y = (Bmax[S])/(Kd+[S]), where Bmax is the maximal level of binding, [S] is the 
concentration of primer DNA, and Kd  is the equilibrium binding constant 178. We will calculate 
Kd, because it provides a direct equilibrium measurement of affinity. Primer Km (the primer 
concentration at which half maximal telomerase activity is observed) is not always an accurate 
measure of primer affinity because it is an indirect measurement of affinity derived from activity. 
Previous groups have determined that the Km does not accurately reflect primer affinity (Kd) for 
human telomerase 154.  
Since we know that telomerase can incorporate 6-thio-dGTP opposite template rA and rC, 
our next question is if telomerase can extend telomeric DNA when 6-thio-dG has already been 
incorporated into the telomere. The Opresko lab and others previously reported that when 
telomeric DNA is oxidized to form 8-oxoG, telomerase activity is enhanced because secondary G-
quadraplex structures are destabilized 91,92.  Telomeric single stranded overhangs in cells have 8-
30 repeats and can fold into G-quadraplex structures, which disrupt telomerase loading. We will 
use direct telomerase assays to test several (TTAGGG)3 (3R) or (TTAGGG)4  (4R) 
oligonucleotides with a site specific 6-thio-dG modification at various locations on the telomeric 
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DNA overhang. The 3R substrate will be used because it is unable to form a GQ structure, while 
the 4R substrate will allow us to test the biologically relevant GQ structure. We will also stimulate 
telomerase with POT1-TPP1, to determine if the complex can promote improved extension. Based 
on our previous findings that terminal 8-oxo-dGTP does not impair telomerase loading, we expect 
that the terminal 6-dG substitution in 3R will minimally affect telomerase processivity. Similarly, 
we expect that the 4R substrate with 6-thio-dGTP will be poorly extended by telomerase. These 
experiments will allow us to determine if telomerase can extend telomeres after 6-thio-dGTP has 
been incorporated, and if 6-thio-dGTP destabilizes secondary G-quadraplex structures.  
To determine the mechanism of the enhanced telomerase activity, we will use a single 
molecule approach with a high molecular resolution to probe the GQ structure with 6-dG. In earlier 
studies using single molecule fluorescence resonance energy transfer (smFRET), 8oxoG in an 
oligonucleotide telomeric overhang induces G4 structure dynamics and perturbations which 
enhance telomerase binding and activity. While telomerase cannot access a tightly folded G4, it 
binds and extends a G4 when 8oxoG is present at the second T or G repeat, which suggests that a 
stable G4 in the telomeric overhang can act as a lock which prevents telomerase activity in normal 
cells, but a single lesion can disrupt the G4 and allow for telomerase extension 179. A previous 
study simulated quadraplexes with thioguanine, and showed that primers with multiple 
thioguanines are unable to form cation-stabilized quadraplex 180. Although the thio group has a 
favorable interaction with Na+, it is too bulky and it leads to expulsion of the cations from the 
channel and collapse of the quadraplex on the nanosecond scale. However, when there is only one 
thioguanine incorporated into the stem, the structure remains stable, but there are local fluctuations 
around the thioguanine 180. These studies examined runs of Gs, however we would like to know if 
6-thio-dG can disrupt the otherwise tightly folded telomeric G4. We will collaborate with the Sua 
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Myong lab to prepare single molecule fluorescence energy transfer (smFRET) of telomeric GQ 
folding with 6-dG. We will design primers with FRET pair dyes Cy3 and Cy5 attached at both 
ends of the GQ forming primer with 6dG. Once we have tested the constructs using smFRET, we 
will use a single molecule pull down (SiMPull) assay with the same primers. The SiMpull assay 
is a method which applies FLAG tagged telomerase to single molecule slides coated with an anti-
FLAG antibody 181. The primers labeled with Cy3 without biotin will be applied to the telomerase 
bound surface and a dual excitation detection will be performed to capture both signals from 
telomerase and the bound DNA substrate. We will calculate the relative binding affinity of each 
construct for telomerase and normalize it against an unfolded positive control (TTAGGG)3. These 
studies will allow us to understand the telomerase binding affinity when 6-thio-dG is in the 
telomeric DNA.  
6.1.2 If cells are treated with 6-thio-dG, can telomerase further extend telomeres? 
Previous studies have shown that treating cancer cells with 6-thio-dG causes telomere 
shortening. What remains unknown is if telomerase can extend telomeres when the cancer cells 
are treated with 6-thio-dG. To determine this, we will use a mutant telomerase cell line that adds 
a well-tolerated variant telomeric repeat sequence to telomere ends 182. By specifically detecting 
the addition of these variant repeats, we will be able to directly visualize telomere elongation 
events in human cells 182. We will express a modified telomerase RNA moiety containing a 
mutant template (referred to as TSQ1) from a retroviral vector in wildtype and mutant human lox 
melanoma cell lines. Instead of the normal 5’-TTAGGG-3’ telomeric DNA repeats, TSQ1-hTR 
has a modified template, so that telomerase adds 5’GTTGCG-3’ repeats to the 3’ ends of telomeres 
104. We will treat the cell lines with 1 µmol/L or 10 µmol/L of 6-thio-dG for long as the cells can 
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tolerate the drug, and collect total DNA at multiple time points. We will look at the incorporation 
of TSQ1 repeats into telomeric DNA by southern hybridization of total DNA with TSQ1 specific 
probes. We will normalize the TSQ1 signal to an Alu signal relative to the wild type. We expect 
that the TSQ1 repeats will rapidly decrease during the duration of 6-thio-dG treatment. 
 
Figure 23. Schematic of wild type and TSQ1 mutant telomerase  demonstrates  synthesis of TSQ1 (5’-
GTTGCG-3’)n telomeric repeats. 
 
6.1.3 Can NUDT15 or MTH1 act on 6-thio-dG? In NUDT15 depleted cells, will 6-thio-dG 
efficacy increase? 
NUDT15 (NUDIX hydrolase 15, also known as MutT homolog (MTH2)) belongs to the 
NUDIX hydrolase family, which is the same family as MTH1. NUDT15 is capable of hydrolyzing 
various oxidized nucleotides, however compared to MTH1, it has 40-fold less enzymatic activity 
toward 8-oxo-dGTP in vitro and in cancer cells. NUDT15 can also decap methylated mRNAs, 
which signifies it has an alternative role in mammalian cells 183. NUDT15 interacts with the 
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polymerase clamp PCNA (proliferating cell nuclear antigen), which suggests that sanitation of 
modified nucleotides could occur at distinct locations, such as the DNA replication fork 184. When 
NUDT15 binds to PCNA, it protects the replication fork from degradation, whereas UV irradiation 
causes dissociation of the NUDT15-PCNA complex and PCNA degradation 184. Recently, a 
missense mutation of NUDT15, R139C was discovered in Korean patients with inflammatory 
bowel disease185. It was correlated with thiopurine intolerance in acute lymphoblastic leukemia 
(ALL) 186,187 and inflammatory bowel disease (IBD) in patients of Asian descent 188.  
Finally, NUDT15 is a key enzyme in thiopurine metabolism and decreases the activity of 
thiopurine drugs by catalyzing hydrolysis of 6-thio-dGTP and 6-thio-GTP. The Helleday 
laboratory resolved the first crystal structure of NUDT15 in complex with 6-thio-GMP bound in 
the active site, showing the key determinants for the substrate specificity. In vivo studies 
investigated whether the depletion of the protein increases efficacy of 6-thioguanine in a cellular 
setting 189. They depleted NUDT15 in human colon cancer cells (HCT116 and MLH deficient 
HCT116-3-6) using doxycycline inducible NUDT15 specific shRNA 189. Clonogenic survival was 
assessed with increasing doses of 6-thioguanine. Depletion of NUDT15 dramatically increased the 
sensitivity of HCT116 3-6 cells to 6-thioguanine, showing that NUDT15 reduces the efficacy of 
6-thioguanine treatment 189.  
Previous studies have demonstrated that 6-thio-dG and 6-thioguanine had similar IC50 
values in cancer cells, but 6-thio-dG was less toxic in mouse models,  making it an attractive drug 
for cancer therapy 128.  We predict that if NUDT15 is depleted in cancer cells, 6-thio-dG efficacy 
will increase, causing more rapid telomere shortening and dysfunction. To complete this study, we 
will first deplete NUDT15 in HCT116 cells using shRNA to compare cell viability and telomere 
length between 6-thio-dG and 6-thio guanine treated cells.   
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Cancer cells with short telomeres are more sensitive to telomerase inhibition than cancer 
cells with long telomeres, because critically short telomeres require telomerase extension at each 
cycle for cell viability 190. We predict that cells with critically short telomeres undergoing 6-thio-
dG treatment will be more vulnerable to NUDT15 inhibition, since 6-thio-dG disrupts telomerase 
translocation and causes rapid telomere shortening.  We will deplete NUDT15 by targeting 
shRNAs in HeLa cells with very short telomeres (HeLa VST) 91 and HeLa cells with long 
telomeres (HeLa LT) 91 and treat both with 6-thio-dG. We predict that the HeLa VST cells will 
exhibit inhibited cell proliferation and induced apoptosis. To determine if there is more telomere 
dysfunction in the NUDT15 depleted cells, we will analyze 53BP1 foci localized at telomeres. 
53BP1 is a DNA damage response protein which localizes to dysfunctional telomeres or 
chromosome breaks 191. 53BP1 foci at telomeres are referred to as TIFs for telomere dysfunction 
foci. We will also complete telomere fluorescence in situ hybridization (FISH) on metaphase 
chromosomes to determine if NUDT15 deficiency in addition to 6-thio-dG treatment increases 
telomere loss and fragile telomeres in both the HeLa VST and LT. Since 6-thio-dGTP will be 
incorporated into the telomeric DNA, TRF1 will not be able to effectively bind to the DNA, 
causing telomere fragility. We predict there will be more telomere loss in the HeLa VST, since 
they will have a higher level of critically short telomeres.  
 90 
 
6.1.4 Can 6-thio-dG be used as an antiviral treatment for COVID-19 or HIV? 
Coronaviruses (CoVs) are genetically diverse positive-sense single stranded RNA viruses 
which circulate in animals and humans. A novel coronavirus, severe acute respiratory syndrome 
coronavirus 2 (SARS-COV-2), was first identified in December 2019 as a cause of respiratory 
Figure 24. NUDT15 depletion causes elevated telomere dysfunction.  NUDT15 is a thiopurine hydrolase which hydrolyses 6-
thio-dGTP into 6-thio-dGMP so that it cannot be incorproated into DNA.  If NUDT15 is depleted from cells, we predict 
there will be elevated amount of 6-thio-dGTP in the cell, which would cause rapid telomerase inhibition, shorter telomeres, 
and apoptosis. Created with Biorender. 
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illness designated as coronavirus disease 2019, or Covid-19. According to the most recent data 
from the John Hopkins COVID-19 resource center, this severe respiratory disease has caused 
600,000 global deaths within a span of 6 months. Currently there is no vaccine, and development 
of an effective vaccine could take 18 months, so it is critical to find an effective therapeutic to 
decrease the overall death toll from this pandemic. Multiple therapeutic agents have been tested 
for the treatment of Covid-19, but none are effective because the virus can adaptively overcome 
negative selective pressure and counteract drugs through the action of a proofreading 
exoribonuclease.   
Remdesivir (RDV) is a prodrug that is intracellularly metabolized to an analog of adenosine 
triphosphate, which inhibits viral polymerases 192. Remdesivir has a broad-spectrum activity 
against members of several viruses, including Ebola and Coronaviruses. Remdesivir (GS-5734) 
inhibits the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV 
and Middle East respiratory syndrome (MERS-CoV). When the viral RNA dependent RNA 
polymerase (RdPr) incorporates the active metabolite remdesivir triphosphate (RDV-TP), it was 
more efficient inhibiting RNA transcription than the natural substrate, dATP, and leads to delayed 
chain termination 3 nt downstream of incorporation.  
Remdesivir has been identified as a promising therapeutic candidate for Covid-19 because 
it can inhibit SARS-CoV-2 in vitro. Also, in primate studies, Remdesivir reduced lung virus levels 
and lung damage 12 hours after inoculation with MERS-CoV 193. It was recently reported that 
Remdesivir inhibits SARS-CoV-2 replication in Calu3 human lung cells and in primary human 
airway epithelial cultures 194. A comparably lower potency of RDV was detected in established 
human and monkey cell lines, because they had a lower metabolic capacity to activate the 
compound. They found that mice infected with a chimeric SARS-CoV encoding the SARS-CoV-
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2 RNA dependent RNA polymerase (RdRP) and treated therapeutically with RDV showed 
decreased viral loads in the lungs and improved pulmonary function, suggesting that RDV is a 
promising therapeutic candidate for COVID-19 194. 
Remdesivir has recently been used on a compassionate use basis for patients hospitalized 
with COVID-19, which were receiving oxygen support or mechanical ventilation 195. Clinical 
improvement was observed in 68% of the patients, however 60% reported adverse effects of the 
drug, and 23% reported serious adverse effects such as septic shock, and multiple organ 
dysfunction syndrome.  
Thiopurines have antiviral activity for positive strand RNA viral pathogens such as bovine 
viral diarrhea virus (BVDV)196. Thiopurine metabolism is complex and requires both activation 
and inactivation reactions. Since 6-thio-dG decreases nonspecific thiopurine toxicity and does not 
kill non-cancerous cells128, it could be an effective antiviral treatment for both COVID-19 or HIV-
1 with less side effects. It can be rapidly converted into either 6-thio-dGTP or 6-thio-GTP (for 
RNA insertion) in cells, which could then be incorporated into the viral RNA, blocking COVID-
19 transcription similar to the mechanism of Remdesivir.   
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6.2 NRTI treatment and aging in HIV patients 
In this study, we have shown for the first time that like HIV-RT, NRTIs AZT and ddI 
directly inhibit telomerase by chain termination. This raises the possibility that, not only is 
accelerated aging from NRTIs caused by polymerase γ inhibition, but also due to telomere 
shortening by direct telomerase inhibition. Previous studies118,173 119 have shown that NRTIs cause 
Figure 25. Remdesivir mechanism of action. The active metabolite of Remdesivir, GS-441524, interferes with 
the action of the RdRP and causes a decrease in viral RNA production. We predict, 6-thio-GTP would have a 
similar mechanism of action. Created with Biorender template.  
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telomere shortening and multiple cell lines, and now we have direct biochemical evidence that 
NRTIs inhibit telomerase, so the next steps of this project would be to measure telomere length in 
patients that have been treated with NRTIs for the past thirty years.  
6.2.1 Longitudinal study to measure telomere length in patients that have been treated with 
NRTIs for the past thirty years 
We hypothesize that over a thirty-year span, the telomere lengths of patients treated with 
NRTIs are significantly shorter than their counterparts. Previous studies have shown that highly 
active retroviral therapy (HAART) decreases telomere length. One study found that after two years 
of aggressive antiretroviral treatment in thirty patients, mean telomere length was 500 base pairs 
shorter than healthy controls 197. Another study followed 27 HIV infected individuals that were 
approximately 50 years old, for 18 months during HAART. They found telomere length shortened 
in CD4+ and CD8+ T cells 198. Another group documented telomere lengths of total peripheral 
blood mononuclear cells (PBMCs) from HIV-infected individuals for nine years 199. They found 
the telomere lengths of the HIV infected individuals shortened 2-fold faster in PBMCs compared 
to age matched seronegative controls. For the HIV infected patients, the mean telomere restriction 
fragment (TRF) in the progressors was greater than that in the asymptomatic individuals and both 
were increased compared to the controls 199. The studies show that patients treated with HAART 
therapy have a slight decrease in telomere length during a short duration. However, they failed to 
complete studies that were longer than two years. Additionally, they have mixed groups of patients, 
which make it difficult to correlate if the telomere shortening is from normal biological aging or 
from the retroviral therapy. In order to test this, will complete a thirty-year longitudinal study using 
the Multi Center AIDs Cohort (MACS).  
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MACS was initiated in 1983 and investigates the natural history of untreated and treated 
human immunodeficiency virus (HIV)/AIDS in a cumulative total of 6972 men in four centers 200.  
The men in the MACS are followed at 6 month intervals, when they complete a questionnaire 
which includes medical history, quality of life, and medications including antiretroviral drugs 200. 
They also have blood collected, which is divided into serum, plasma, and cells. As of May 2011, 
the MACS had accumulated 87,000 person-years of follow up in incorporating 8920 variables. 
This allows MACS to have data and specimens which document the entire natural history of 
HIV/AIDS from pre-infection, through infection, pre-treatment and treatment, to cause-specific 
death 200. The cohort also includes comparison groups of similar risks to those of interest, such as 
uninfected men. This will allow us to complete a standardized, complete longitudinal study of 
telomere length in specimens collected uniformly across centers before and after infection and 
treatment.   
To determine if HIV patients undergoing HAART have faster telomere shortening rates 
than healthy controls, we will perform a longitudinal study by selecting specific criteria from the 
MACS participants. We will select at least 50 patients who initiated HAART while enrolled in the 
MACS. Selection criteria will include the following characteristics: an age range of 20-30 years, 
viral load >50 copies/mL with a successful response to treatment 201. We will age match MACS 
participants who have received HAART without NRTIs as a negative control. We will use samples 
at 5 year intervals. Since the average telomere length decreases by 25 bp per year, length would 
be difficult to distinguish on a southern blot at less than 5-year intervals. We will extract the DNA 
from the PBMC samples by a commercially available kit from Qiagen. Contaminants and enzyme 
inhibitors are removed by salt precipitation, which results in purified DNA that is available for 
immediate use. The kit can also be used for high-throughput processing of multiple samples, which 
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makes it useful for this large-scale epidemiological study. After the DNA has been extracted, we 
will evaluate the DNA integrity using agarose gel electrophoresis, and visualize with SYBR green. 
We will then digest at least 3μg of genomic DNA with restriction endonucleases Hinf1 and Rsa1 
202. This allows for a mean telomere length that is longer than 1kb. We will resolve the samples on 
an agarose gel, and probe with a 5’ radiolabeled (TTAGGG)3 oligonucleotide. To measure the 
final TRF length, we will use ImageQuant TL and adjust for the higher signal intensity obtained 
from longer TRFs, as the telomere probe hybridizes several times to the fragments 202. For this 
epidemiological study, the TRF length will be calculated by integrating the optical density of each 
telomeric smear and interpolating the mean telomeric length from the molecular weight ladders 
202. To analyze the epidemiology data, multivariable linear regression will be used to identify 
factors predictive of telomere length at the baseline. Although Southern Blots are optimized in the 
Opresko lab, there may be challenges with the integrity of the genomic DNA from the MACS. The 
long term PBMC samples may have degraded which could yield poor quality DNA or less than 
3μg necessary for Southern blots. If this occurs, quantitative PCR (qPCR) of mean telomere length 
can be used. This allows for approximately 50ng of DNA per sample, however only the average 
telomere length is measured 202.  There may also be selection bias in our analysis due to individuals 
with aging disorders or environmental factors such as cigarette smoking. Additionally, modeling 
telomere dynamics may pose a challenge because telomere repeats are proportional to the length 
of telomeres 203. Longer telomeres may provide a larger target for free radicals 203.  
We expect that telomere length will significantly decrease over time in patients treated with 
NRTIs versus those not treated with NRTIs (Figure 26).  This longitudinal analysis will allow us 
to look at telomere lengths over a 30-year period so we can correlate if NRTIs have a direct effect 
on aging phenotypes.  
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6.3 Final conclusions  
This study deciphers the mechanism by which telomerase can insert oxidized and 
therapeutic dNTPs into telomeric DNA.  6-thio-dGTP can disrupt telomerase translocation and 
NRTIs inhibit telomerase by chain termination. Understanding how telomerase incorporates these 
modified nucleotides paves the way for multiple new projects involving biochemistry, cell biology, 
and use of clinical samples. Using biochemistry assays such as binding kinetics and smFRET, 
when the modified dNTPs have already been incorporated into the DNA, we can determine if 
telomerase can bind to the telomeric DNA. In cells, we can further understand how the modified 
Figure 26. Telomere shortening rates hypothesisWe hypothesize that HIV infected individuals 
undergoing HAART will have faster rates of telomere shortening than healthy controls. We will 
select patients from the Multicenter AIDS Cohort Study (MACS) and measuring their telomere 
length at 5 year intervals.  
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dNTPs damage telomeres. A longitudinal cohort study would answer the longstanding question 
about the rate of telomere shortening in HIV-1 patients undergoing long term HAART.   Thus, the 
future studies and collaborations will have important health implications for potential off target 





7.0  Statement of Public Health Significance 
 
Recent therapeutic strategies for treating HIV and advanced cancer patients have increased 
their overall survival rate. Both targeted therapies and cancer immunotherapies have allowed these 
patients to have prolonged remission and improved quality of life. Unfortunately, both HIV and 
many advanced cancers develop drug resistance. In order to improve patient survival rates, it is 
necessary to understand the molecular mechanisms in which the virus or tumors develop resistance 
to existing therapies.  
A characteristic of advanced cancers is their ability for continuous cell divisions, which 
most frequently involves maintaining telomere length by reactivating telomerase.  Telomerase is 
a prime target for effective therapies against cancer, because normal human cells either lack 
telomerase or have lower telomerase activity and maintain telomeres at longer lengths compared 
to cancer cells. Fast acting therapeutic agents, such as modified nucleosides, which inhibit 
telomerase, are highly desirable treatment options. The modified nucleoside could be incorporated 
into the telomeric DNA, which would cause telomere shortening and rapid cell death.  Until this 
study, the mechanism by which telomerase incorporates these modified nucleotides remains 
unknown. 
 Here, we uncover the mechanism by which several modified nucleotides compromise 
telomere maintenance. The NRTIs (AZT and ddITP) inhibit telomerase by acting as chain 
terminators. 6-thio-dGTP and 2-OH-dATP disrupt telomerase translocation. Furthermore, the 
modified nucleotides used in this study not only inhibit telomerase, but reports show they also 
inhibit the mitochondrial DNA polymerase γ, leading to mitochondrial dysfunction and elevated 
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ROS which damage dNTP pools 120,131. Therefore, in conjunction with MTH1 inhibitors, our 
studies suggest therapeutic NRTIs or thiopurines may deliver a one-two punch to telomerase 
driven cancers by inhibiting telomerase directly and indirectly through elevated oxidized dNTPs. 
This study has important health implications for potential off target effects on long term NRTI 
treatments in HIV patients, and for therapeutic strategies to target telomerase in cancer. 
101 
 102 
Appendix A Telomerase inhibitors 
Table 4. Telomerase inhibitors 
Therapeutic 
approach 






Targets RNA template of 
telomerase 
Inhibition of tumor cell 






Direct enzyme inhibitor of 
TERT via active site binding 
Inhibition of tumor cell 










Nucleotide analog blocks 
the reverse transcription 
process by chain termination 
 
Telomere shortening. 119,123,127 
Didanosine hTERT Telomere shortening. 119 





Nucleotide analog blocks 
the reverse transcription 





5-FDU hTERT Telomerase inhibition Telomere shortening 137 
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hTERT promoter drives the 
expression of a pro 
apoptotic suicide gene 
Tumor cell lysis 
212 
CB1954 
TERT promoter expression 
of an enzyme required for 








Inhibits recruitment of 
hTERT to the nucleus 
Down regulation of 








Stops telomerase from 
adding further repeats 
Induce telomere shorting, 





Stops telomerase from 
adding further repeats 
Induce telomere shorting, 
block the cell cycle, and 
induce apoptosis 
216 
















Appendix B  Azidothymidine and 6-thio-dG dosing from pre-clinical or clinical studies  
Table 5. Azidothymidine and 6-thio-dG dosing from pre-clinical and clincial studies  
Drug Dose Study model and cancer 
type 
Study Conclusions  Reference 
AZT   Administered in doses of 
2, 3, 4, 5.5, 7, 8.5, 10, 12, 
15, or 20 g/m2/day as a 
continuous infusion over 
48 hours. Patients also 
received fluorouracil plus 
leucovorin for 24 hours 
before the start of and 
during the ZDV infusion. 
 
Fourteen patients (6 women) 
with solid tumors that were 
unresponsive to standard 
therapy received 31 courses 
of therapy. 
 
Highest doses of the 
drug were optimal  
220  
AZT + Methotrexate Treated with weekly oral 
methotrexate (7.5 
mg/M2 every 6 hours for 
6 doses) and continuous 
oral AZT (200 mg four 
times daily). 
 
31 patients with 
adenocarcinoma of the 
pancreas or hepatocellular 
carcinoma  
 
One patient achieved 
a radiographic 
complete remission 
and 2 had stable 
disease. Two-thirds 
of patients 
progressed within 2 





AZT + Cisplatin AZT was administered as 
a 72-h infusion on days 1-
3 and 14-16 of a 28-day 
cycle at dose levels from 
400 through 14,364 
mg/m(2) per day. CDDP 
at dose levels of 30, 45, 
or 60 mg/m(2) was 
administered at hour 36 
of each AZT infusion.  
 
61 patients with advanced, 
histologically confirmed 
malignancies which were 




Of the 61 patients 
who completed 125 
courses of therapy, 
21 had stable disease 
for a median of four 
cycles (range two to 
eight), 33 progressed 
on therapy, and 7 
were not assessable 





6-thio-dG 2.5 mg/kg of 6-thio-dG 
every 2 days   
Pediatric high-risk group 3 
medulloblastoma (tumors 
were injected into syngeneic 
(immunocompetent) tumor 
growth mouse model. 
Four of six treated 
mice had reduced or 
delayed tumor 
growth. Two of the 
six treated mice 
showed fast tumor 
growth, most likely 
due to the tumor 
aggressive nature and 
larger tumor volume 





6-thio-dG  5 mg/kg of 6-thio-dG, for 
12 days 
 
Tumor volumes of 
xenografts of 6 patient or 
mouse derived cultures of 
therapy resistant melanoma 
6-thio-dG both in 
vitro and in vivo that 
results in telomere 
dysfunction, leading 
to apoptosis and cell 
death in various 
preclinical models of 
therapy-resistant 
melanoma cells.  
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6-thio-dG 5 mg/kg of 6-thio-dG, for 
14 days 
 
KRAS mutant genetically 
engineered mouse model 
(KRASLA1) of lung cancer 
66% reduction in 
tumor volume with 
6-thio-dG treatment  
 
176 
Thiopurine (6-MP) Remission maintenance 
chemotherapy for this 
trial consisted of daily 
oral 6-MP and weekly 
oral methotrexate at 
starting doses of 75 
mg/m2 and 20 mg/m2 
 
50 children with ALL who 
were receiving remission 
maintenance chemotherapy,  
 
During chronic 
therapy with 6-MP or 
azathioprine, patients 









6-thio-DG Seven days after tumor 
inoculation (when the 
tumor volume was 100 
mm3), 3 mg/kg 6-thio-dG 
was administered daily 
MC38 (colon cancer) cells 
injected into mouse models  
MC38 tumor cells 
are sensitive to 6-
thio-dG 
with a half maximal 
inhibitory 
concentration (IC50) 
of 370 nM 
225 
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Appendix C Doses of NRTIs and Thiopurines used in the clinic  
Table 6. NRTI dosing and combinations for HIV patients from UPToDate Clinician Database 
NRTI Combination Drug Name Dosage 
Lamivudine/Zidovudine  Combivir (COM) 150/300mg tabs 
Abacavir/Lamivudine/Zidovudine Trizivir (TZV) 300/150/300mg tabs 
Tenofovir/Emitricitabine Truvada 300/200mg tabs 
Abacavir/Lamivudine Epzicom 600/300mg tabs 
Tenofovir/Emtricitabine/Efavirenz Atripla 300/200/600mg tabs 
 
Table 7. Thioguanine dosing from UpToDate Clinician Database  
Disease type Adult dose Pediatric dose  
Acute myeloid 
leukemia  
Oral: 2 mg/kg once daily for 4 
weeks; if no clinical improvement after 4 
weeks and ANC and platelet counts are not 
depressed, may increase dose to 3 mg/kg 
once daily with careful monitoring.  
Delayed intensification treatment phase: 
Children ≥1 year and Adolescents: Oral: 
60 mg/m2/dose once daily for 14 days 




Oral: Late intensification 
treatment phase: 60 mg/m2 once daily on 
days 29 to 42 (in combination with 
doxorubicin, vincristine, dexamethasone, 
cyclophosphamide and cytarabine)   
Infants and Children <3 years: 
Oral: 3.3 mg/kg/day divided once or 
twice daily for 4 days in combination 
with cytarabine and daunorubicin 
 
Children ≥3 years and Adolescents: Oral: 
100 mg/m2/day divided once or twice 
daily for 4 days in combination with 
cytarabine and daunorubicin 
CNS tumors, low 
grade gliomas 
--- Children <10 years: Oral: 30 mg/m2 
every 6 hours x 11 doses (from hours 0 to 
66) in a 42-day cycle for a total of 8 
cycles (in combination with 
procarbazine, lomustine, and vincristine) 
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Appendix D Nature Communications Rebuttal  
Rebuttal letter submitted to the reviewers of Nature Communications for my first author 
paper, “Mechanisms of telomerase inhibition by oxidized and therapeutic dNTPs”. Currently 
with assigned reviewers as of July 28, 2020.  
 
We thank the reviewers for their helpful comments and have addressed each in detail as 
described below.  Modifications and additions to the manuscript in response to the reviewers’ 
suggestions are indicated in red text, and we believe strengthen the overall study.   
 
Reviewer #1 (Remarks to the Author): 
 
Approximately 85% human tumors maintain telomeres through telomerase. Disruption of 
telomerase-mediated telomere repeat addition would affect telomere maintenance and ultimately 
cancer cell growth. Previously, this group reported that insertion of 8-oxo-dGTP by telomerase 
terminated telomere elongation in vitro. They demonstrated that depletion of MTH1, which 
hydrolyzes oxidized dNTPs (e.g. 8-oxo-dGTP), inhibits telomere maintenance in cancer cells 
grown under oxidative stress conditions. In this study, the authors used the same in vitro 
telomerase extension assay to investigate the mechanisms by which several modified dNTPs 
(oxidized and therapeutic dNTPs, including 2-OH-dATP and 6-thio-dGTP) could disrupt 
telomerase repeat extension and translocation. In addition, they reported that the telomerase 
processivity factor POT1-TPP1 failed to restore processivity of telomerase in the presence of 
these inhibitory dNTPs. The in vitro experiments were well conducted. However, the major 
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weakness of this manuscript is the lack of evidence demonstrating that these modified dNTPs 
disrupt telomere maintenance and cell survival in human cancer cells. 
 
Although inhibiting telomerase activity is a promising therapeutic strategy to treat many cancers, 
this approach may disrupt telomere maintenance and viability of human germline cells, stem 
cells, and progenitor cells. In addition, inserting therapeutic dNTPs in the genome of healthy 
proliferating cells may occur, which would block DNA replication and lead to genomic 
instability. Thus, experimental studies that would have enhanced my enthusiasm for the current 
study would have included testing to determine if these therapeutic dNTPs affected cell growth 
of healthy and telomerase positive cancer cells differently. 
 
Below we summarized the published studies that have shown oxidized and therapeutic 
dNTPs particularly impact the growth of telomerase positive cancer cells.  We reference this 
work in our introduction and discussion.  Our goal in the current manuscript was to elucidate the 
mechanism of induced telomere shortening.     
 
We and others previously reported that MTH1 depletion disrupts telomere maintenance 
and telomerase activity in cancer cells grown under oxidative stress conditions, and that 
telomerase insertion of 8-oxo-dGTP terminates further telomere elongation in vitro 91 92.  
Previously studies show that cancer cell lines are more sensitive to MTH1 inhibition compared to 
normal human cell lines101. MTH1 removes other oxidized dNTPs besides 8-oxo-dGTP, 
including 8-oxo-dATP and 2-OH-dATP, which we tested directly for telomerase inhibition in 
this manuscript.   
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In 2001, a study reported that chronic AZT treatment of mouse mammary carcinoma cell 
lines inhibited telomerase activity, caused progressive telomere shortening, and led to cellular 
senescence and apoptosis 46. This study demonstrated for the first time that AZT-treated tumor 
cells reduced tumorigenicity in BALB/c mice. Additional studies showed that AZT reduced 
tumor growth in rats with parathyroid cancer cells or hepatocellular carcinomas 123. 
 
The Shay and Wright labs, and collaborators, have published extensive cell and mouse 
model studies investigating the effects of 6-thio-dG on telomere maintenance, toxicity and tumor 
growth in vivo. They found that 6-thio-dG treatment caused telomere dysfunction, as evidenced 
by telomere dysfunction induced foci (TIFS), only in telomerase expressing cells, but not in 
telomerase negative cells 128.  Compared to other telomerase inhibitors, 6-thio-dG caused a faster 
rate of telomere shortening, and resulted in rapid cell death in numerous cancer cell lines, while 
normal human fibroblast and epithelial cell lines were largely unaffected.  They also found that 
6-thio-dG was less toxic to mice compared to equal amounts of 6-thioguanine, but still decreased 
tumorigenicity of lung tumor xenografts.  In other pre-clinical models, 6-thio-dG treatment 
controlled the spread of a therapy resistant form of melanoma 135. In xenograft models, 6-thio-dG 
halted tumor growth 135. Additional pre-clinical studies have shown that 6-thio-dG induced 
telomere dysfunction in a telomerase dependent manner in both lung and pediatric brain cancers, 
resulting in reduced tumor growth 176, 136.  
 
Since multiple previous studies had confirmed that treatments with various oxidized and 
therapeutic dNTPs cause telomere shortening in telomerase positive human cancer cell lines and 
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in xenograft tumors, our goal was to elucidate the mechanism of telomere shortening and 
telomerase inhibition. 
 
Minor comments: As a negative control, please include RNAse A treatment in 
Supplemental Figure 1. 
 
We included an RNase A control in Supplemental Figure S3 demonstrating that the poly-G 
laddering and telomerase activity is dependent on the RNA template. However, we inadvertently 
left out reference to this important control in the original version, and apologize for this 
omission. We added reference this control on page 6 (1st paragraph). 
 
Reviewer #2 (Remarks to the Author): 
 
The study is clearly presented, and the experiments are well designed and, for the most part, 
appropriately interpreted. However, there are several points the authors should consider in a 
revised manuscript, before the paper would be appropriate for publication. Provided the authors 
can address these concerns, this excellent work will certainly be of interest to the broad 
readership of Nature Communications. 
 





1. A major conclusion stated throughout the manuscript is that the action of 6-thio-dG perturbs 
the translocation step and in turn results in lower repeat addition processivity. However, it is 
clear in Fig. 4c that the presence of 6-thio-dG causes a major stall mid-way through the first 
telomere repeat when extending Primer #2. Thus, it is unclear that the effects of this compound 
and several of the others can be unambiguously linked to specifically the ‘translocation’ step of 
the telomerase catalytic cycle. That said, it is clear that the impacts of 2-OH-dA and 6-thio-dG 
are distinct from traditional chain terminators, which is very interesting indeed. However, the 
authors should consider revising their paper to tone down the specific link with the translocation 
step and might consider stating that these nucleotide analogs impact the efficiency of RAP more 
generally (which might relate to steps other than translocation per se). 
 
We thank the reviewer for pointing this out, and apologize for the lack of clarity.  We 
agree that 2-OH-dATP and 6-thio-dGTP impact more than just the translocation step, since we 
see effects not only on repeat addition processivity, but also on nucleotide addition processivity.  
Now, we clearly defined repeat and nucleotide processivity in the text, and the steps involved 
(pages 3-4, and Figure 1), and clarify throughout the manuscript whether we are referring to 
repeat or nucleotide processivity.  Repeat processivity requires dissociation from the product-
template duplex, template repositioning and reannealing to initiate synthesis from the primer 3’ 
end, and active site stabilization of the duplex at the template 3’ end to add a telomeric repeat. 
Nucleotide addition processivity is defined as the number of nucleotides added before the 
enzyme reaches the 5’ template end and dissociates. Therefore, disruption in nucleotide 
processivity can lead to premature truncation prior to adding the 6 nucleotides to complete 
synthesis of the GGTTAG repeat.  We agree that our data in Figure 4 indicates that 2-OH-dATP 
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and 6-thio-dGTP are general processivity disrupters, and that they disrupt nucleotide processivity 
resulting in termination prior to complete repeat synthesis, and repeat processivity resulting in 
termination after one repeat is added. We added statements to better describe these results, and 
the effect of these modified dNTP on repeat processivity more generally, on pages 7 and 8 
(marked in red).   
 
2. The experiments describing the mixed effects of adding back the telomerase cofactor, POT1-
TPP1, appear to be somewhat flawed. While not completely understood, the existing structural 
and functional data on the interaction of POT1-TPP1 with the telomerase-DNA complex would 
suggest that the schematic drawn in Fig. 5c is not possible. In other words, using the short 3-
repeat DNA primer, one would expect that POT1-TPP1 will not have access to its binding site 
within the 5’ region of the DNA primer until more DNA has been synthesized. In fact, one could 
interpret the data presented in this figure to suggest that the ability of telomerase to more readily 
incorporate 8dA and 2dA provides an opportunity for POT1-TPP1 to augment processivity as 
shown in Fig. 5a. In contrast, since 6dG, ddI, and ZdT do not support addition of more than one 
repeat, one would not expect POT1-TPP1 to exert any effect on the reaction, as is shown in Fig. 
5b. A more informative experiment might be to do the experiment with longer starting primers to 
determine whether POT1-TPP1 that has access to the 5’ end of the DNA can somehow suppress 
the defects observed in the presence of 6dG. Based upon the data presented in this study, I would 
expect that the authors interpretation are likely to stand, this additional experiment may not be 




We considered the possibility that POT1-TPP1 may compete with telomerase for binding 
at the 3’end of the primer.  The schematic in Figure 5c was based on previous published work 
that showed POT1 binds 10 nt of ssDNA (X-ray crystal structure), which is available in this 
primer substrate 226, 227. We used the same substrate (primer a5) shown to be an optimal substrate 
for POT1-TPP1 stimulation of telomerase 226, 15. Our data show that when telomerase is 
stimulated with POT-TPP1, telomerase repeat processivity increases in the presence of 2-OH-
dATP.  This result supports the conclusion that POT1-TPP1 has access to the 5’ end of this 
substrate, and therefore, we do not expect that a longer starting primer would yield a different 
result with POT1-TPP1 and 6-thio-dGTP (i.e. we still expect POT1-TPP1 would not be able to 
overcome the detrimental effects of 6-thio-dG on processivity).  With regards to 8-oxo-dATP, in 
Figure 3 we showed that telomerase very poorly incorporates 8-oxo-dATP opposite any template 
position. Therefore, in Figure 5a, lanes 5 and 6, telomerase is likely misincorporating dGTP or 
dTTP opposite template rU, when dATP is absent, which would explain the extension in both 
lanes.  
 
3. It appears that the structure of 2-OH-dATP is not correct in Fig. 1a, where the authors 
have shown the OH group appended to the ribose moiety rather than the adenosine base at 
position 2.   
 
We thank the reviewer for catching this unfortunate error. We have corrected this in the 
revised Figure 1a.  
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4. With respect to nomenclature – the authors need to define their shorthand for the 
various nucleotide analogs used throughout the paper (perhaps doing so in Fig. 1a makes the 
most sense). 
 
Thank you for this valuable suggestion for improving readability. These abbreviations 
have been added to Figure 1a.  
 
5. The authors should consider using specific template nucleotide numbering when referring to 
telomerase RNA template positions rather than rCrC, for example. 
 
Thank you for this suggestion. We defined the template bases rC1rC2rA3rA4rU5rC6 in the 
figures and the text, and found this greatly improved readability. We did not highlight these 
changes in the text given the abundance. 
 
6. In the discussion the authors claim - "We found that telomerase incorporation of dGTP is more 
error prone than the other natural dNTPs, as indicated by dGTP misincorporation at low 5 μM." 
However, this is a bit misleading as the level of misincorporation at low uM concentrations in 
Fig. S3 is very minimal and only becomes apparent at much high dGTP concentrations. 
 
We agree that the % primer extension is very minimal at 5 M dGTP across non rC 
template resides (6% for primer 1 and 2% for primer 3), but we found this noteworthy because at 
this low physiological concentration we do not see Poly-G laddering.  Furthermore, we observed 
no misincorporation of dGTP even at 200 M by DNA polymerase  (Supplemental Figure 4d).  
 115 
 
On a related note, the authors state, "Interestingly, telomerase extended all three primers 
in the presence of dGTP, indicating telomerase can incorporate dGTP opposite each template 
base even at low cellular concentrations (5 μM) (Supplementary Fig. S3)." This result is not very 
surprising as this G-ladder pattern has been reported previously for both human and cilate 
telomerase systems (as the authors appropriate cite in the paper). Moreover, it is unclear from 
these experiments whether or not this ladder pattern in fact is a result of ‘misincorporation’ 
across from non ‘rC’ template nucleotides, or whether this is due to some form of product 
slippage (as the authors ultimately allude to in the Discussion). The authors should take care to 
differentiate such a slippage model from actual misincorporation events. 
 
We agree that we cannot rule out that product slippage is a contributor, however, we also 
cannot rule out that dGTP may be misincorporated as well. Our data in Figure 3 indicate that 50 
M dGTP reactions for insertion opposite template rA (primer 1) yield 20% primer extension, 
opposite rC (primer 2) show 25% extension, and opposite rU (primer 3) show 5% primer. If 
extension was due only to non-specific poly-G laddering, then we reason the % primer extension 
would be the same opposite all starting template positions, which was not the case.  Furthermore, 
we observed comparable % primer extension for dGTP and 6-thio-dGTP with starting template 
rA (primer 1), yet we observed no evidence for poly 6-thio-dGTP laddering (Figure 3). However, 
as we noted in the discussion slippage may contribute to misincorporation: “This primer slippage 
may contribute to dGTP addition opposite non rC residues, although poly d(G) laddering was not 
observed at low (5 M) dGTP, suggesting addition by misinsertion”. Since we cannot distinguish 
between these two mechanisms, we altered some of the language (page 5, 11, and 12 from 
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“indicate” to “suggests”), and to reflect both of these possibilities.  
 
7. Throughout the paper, the authors cite R1/2 values, yet there is no figure included where the 
data and the associated fits from which they are derived is shown. It would also be a good idea 
for the authors to clearly articulate how the R1/2 value for processivity is defined, which they 
appear to be basing on the work from Latrick and Cech. For example, in the text, the authors 
should not simply state the processivity goes from ‘2.5 to 4.5’, as these numbers are not likely to 
mean anything to readers if the definition for how this value is determined is not clearly 
presented. 
 
We agree with this helpful critique and the lack of clarity on the R1/2 values in our 
original version.  We have added the plots from which R1/2 values were derived to the 
Supplemental figures.  We now define in detail how R1/2 was calculated in the methods.  
Finally, we more clearly explain the meaning of R1/2 in the text on pages 4, and 9. “Repeat 
processivity was measured using the convention of calculating the number of repeats synthesized 
before half of the DNA substrates dissociate from telomerase 228.” 
  
8. Late in Results section of the paper, the authors describe pre-steady state kinetics analysis of 
incorporation by the flour beetle TERT protein using a model hybrid RNA-DNA duplex. The 
abrupt switch to the tcTERT system appears to come out of nowhere since all prior experiments 
in the work are done on human telomerase. Moreover, I could not find any description in the 
Materials and Methods about how this tcTERT was made and what the sequences of the RNA-
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DNA hybrid are? The authors should better justify the transition and to this alternative 
‘telomerase-like’ system from Tribolium casteneum. 
 
Thank you for noting this omission from the methods.  We have added details of the 
purification, and sequences used with the tcTERT reactions to the methods section.  We have 
also referenced a very recent publication 144 which further describes in detail the use of this 
model for comparison with human telomerase catalysis of nucleotide addition.  We have also 
added the following text to page 10, to justify our use of this model. 
 
“We showed previously that the ability to purify sufficient quantities of tcTERT enables 
characterization of the catalytic nucleotide addition by pre-steady-state single turnover kinetics 
using a defined DNA-RNA primer-template substrate 144. This analysis measures the catalytic 
efficiency of incorporating a single dNTP by dividing the observed nucleotide incorporation rate 
constant, kpol, by the equilibrium dissociation constant for dNTP binding to tcTERT-primer-
template complex (Kd) 158.  
 
9. The authors describe an effect of inhibition at high dGTP concentrations of hot-dTTP 
incorporation (Fig. 2a). This is a bit confusing, because in this figure, lane 4, there appears to be 
high MW signal that is not being well-resolved? The authors should explain. Also, is a similar 
inhibition observed at high dGTP when using the 5’ end-labeled primer assay? I suppose one 
would expect the G-ladder pattern to begin to emerge when there is a large excess of dGTP over 
the other dNTPs. 
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The reactions in Figure 2a used radiolabeled dTTP and 10μM of cold dTTP. We found 
that if we added higher concentrations of cold dTTP to the reactions, it would swamp out the 
signal of the radio-labeled dTTP. The high MW products in lane 4 (Figure 2a) are due to high 
telomerase processivity when 125 μM of dGTP was added to the reaction. The signal of these 
products is weak because 1) T makes up of only 30% of each telomeric repeat, and 2) the near 
10-fold excess of dGTP (125 μM) over dTTP competes for insertion opposite rA3.  In 
Supplementary Figure S2 the high MW products are better resolved when the dGTP 
concentration is lower at 25 μM.  When we used radiolabeled dGTP (Figures 2b and 2c), the 
signal of the high MW products is greater partly because G makes up 50% of the telomeric 
sequence.  
 
We would not expect to see loss of radioactive signal using a radiolabeled primer, since 
the product labeling does not depend on insertion of a radio-labeled dNTP.  In Figure 4, the 
reactions were conducted with all the dNTPs, including dGTP, at 50 μM each (see lane 2 of each 
panel).  Here, the higher MW bands appear better resolved with a more even signal for each 
product.  
 
Reviewer #3 (Remarks to the Author): 
 
I find the paper overall strong, with a well-written, logical flow to the experiments. A limitation 
of the experiments is the reliance on one (well defined) in vitro assay. 
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Thank you for the positive feedback. The field as whole has been challenged by 
developing methods and tools to monitor telomerase-mediated telomeric repeat addition and 





The data in figure 2a-c suggests a high tolerance for misincorporation of natural nucleotides 
(particularly dG). The authors should clarify in the text that in vivo telomerase does not seem to 
have such a high false incorporation rate for dG. I think that this is needed to put the in vitro data 
into context. 
 
While we observed misincorporation for dGTP at cellular relevant concentration (5 μM), 
the misinsertion product opposite rA3 was minimal (Supplemental Figure 3).  Furthermore, we 
expect that the higher physiological concentrations of dTTP (~37 M), and the preference for 
telomerase insertion of dTTP opposite rA3 (Figure 3, panel a), would outcompete dGTP in a 
physiological setting.  Because the cellular concentration of dGTP is much lower than dTTP, we 
would not expect to observe high misincorporations of dGTP by telomerase in a cellular context. 
That said, sequencing data on telomeres from cells is limited, and it is possible that accessory 
factors improve telomerase fidelity in vivo.  On page 12 in the discussion we added: 
 
 120 
“The lower physiological concentration of dGTP (5 M), relative to the other dNTPs 150, 
likely minimizes dGTP misincorporation and laddering in vivo. Furthermore, accessory proteins 
may assist telomerase fidelity.”      
 
It would be helpful to educate the reader as early as possible on the physiological nucleotide 
concentrations to put the assay concentrations into context. This is especially important as, based 
on the introduction, the focus seems to be on the development of these dNTPs for clinical use. 
 
This is an excellent point, and we included values for the natural dNTPs (24 μM dATP, 
29 μM dCTP, 37 μM dTTP, 5.2 μM dGTP, averaged from multiple studies150)  at the beginning 
of our results section (page 4).  
 
A few questions come to mind: what are the effects of these modified dNTPs on other 
polymerases; what are the difficulties already encountered with using modified dNTPs for cancer 
treatment; and, how may the new information presented in this article circumvent those 
challenges? 
 
Several studies have shown that the modified dNTPs inhibit mitochondrial DNA 
(mtDNA) polymerase γ (pol γ), which disrupts mitochondrial DNA replication and induces 
mitochondria dysfunction 131, 115. Inhibition of pol γ leads to the depletion of mtDNA, and 
subsequent depletion of mitochondrial encoded poly peptides involved in oxidative 
phosphorylation. When the modified dNTPs cause a decrease in mtDNA, the mitochondria 
protein complex malfunctions, causing changes in respiration rate, decreased ATP production, 
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diminished mitochondria membrane potential, and an increase in ROS production.  The elevated 
ROS damage natural dNTP pools. We suggest that in conjunction with MTH1 inhibitors, 
therapeutic NRTIs or thiopurines may deliver a one-two punch to telomerase driven cancers by 
inhibiting telomerase directly and indirectly through elevated oxidized dNTPs.  The new 
information presented in this article defines the mechanism in which both oxidized and 
therapeutic dNTPs inhibit telomerase, which has previously not been shown. We comment on 




1. Figure 1 lacks quantification and statistics. 
 
Figure 1 shows chemical structures of the modified dNTPs, and the enzymatic schematic 
for telomerase.  We assume the reviewer is referring to Figure 2.  More detailed quantification 
and statistics for Figure 2 are shown in Supplemental Figure 2.   
 
2. Is there a particular reason why the authors did not test a primer ending on GTTA? I think this 
could be a good primer to include in figure 3 and 5 as it most effectively tests the effects of 6dG 
on translocation. 
 
A primer ending in GTTA would be a slight variation of Primer 3 (ending in GGTT). For 
Primer 3, Figure 4 shows a strong termination product after telomerase incorporated 6-thio-
dGTP opposite rC6, suggesting dissociation prior to translocation.  But we also observed a strong 
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termination product at rC1, indicating either successful translocation for some reactions followed 
by dissociation, or template slippage for an additional 6-thio-dGTP prior to translocation.  This 
result was recapitulated with Primer 1.  Therefore, we predict the same result if we used a primer 
ending in GTTA; nearly 50% of the products terminating after insertion opposite rC6, and the 
rest terminating after insertion opposite rC1.  Furthermore, since dATP was included in the 
reactions for Figure 4 and primer 3, the addition of dATP converts the -GGTT ending primer to -
GGTTA prior to insertion of 6-thio-dGTP. 
 
3. A key defect of 6dG incorporation is a reduced inability for telomerase translocation. The 
effect seen is relative and it would be good to corroborate this with an orthogonal (in vivo) assay. 
The same is true for the lack of stimulation in Figure 5. 
 
We are not aware of any current techniques to measure telomerase translocation directly 
in vivo, although some labs are developing methods for tracking telomerase movement in cells 
229, 230. Notably, even these novel techniques lack the resolution required to visualize telomerase 
translocation at telomeres in cells.  However, we are excited by studies that show 6-thiodG 
treatment causes telomere shortening in telomerase positive cancer cells in culture, and telomere 
dysfunction in the tumors.  Our purpose for this study was to elucidate the mechanism by which 
6-thiodG induces telomere shortening in telomerase expressing cancer cells. 
 
Minor comments: 
Citation 22 is a review from 2008 -- is there anything more current? 
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We have added more recent reviews: 
Schmiegelow et al, J Pedr Hematol Oncol, 2014 
Bradford et al, World J Gastroenterol, 2011 
Zhang and Shay, Oncotarget, 2018 
 
In reference to this sentence, “Previous reports showed that 6-thio-dGTP, which forms in cells 
from 6-thio-dG, promotes cell death in telomerase positive cancer cells, and decreases tumor 
growth in mouse xenograft studies23” -- Citation 23 is not the original source for this 
information. Citation 23’s authors have a patent for 6-thio-dG, and in this article, they are 
summarizing their past results. Would it be possible to use a different citation for this 
information? 
 
To our knowledge Citation #23 in the original version of our article (Mender et al, Cancer 
Discovery, 2015) is the first publication by the Shay/ Wright group we could find in which they 
report evidence that 6-thio-dG causes telomere dysfunction. The primary data that “6-thio-dG 
promotes cell death in telomerase positive cancer cells” are shown in Figures 1 and 3, and 





Appendix E Mechanisms of nucleotide selection by telomerase  
Our collaboration with the Freudenthal Lab at University of Kansas Medical center resulted 
in a research article originally published in eLife 144. Mechanisms of nucleotide selection by 
telomerase. Matthew A Schaich, Samantha L Sanford, Griffin A Welfer, Samuel A Johnson, Thu 
























Appendix F Position-Dependent Effect of Guanine Base Damage and Mutations on 
Telomeric G-Quadruplex and Telomerase Extension 
Our collaboration with the Sua Myong Lab at Johns Hopkins University resulted in a 
research article originally published in Biochemistry 179. Position-Dependent Effect of Guanine 
Base Damage and Mutations on Telomeric G-Quadruplex and Telomerase Extension. Hui-Ting 
Lee, Samantha Sanford, Tapas Paul, Joshua Choe, Arindam Bose, Patricia L. Opresko, and Sua 

















Appendix G Practice makes progress 
 
Figure 27. “Practice doesn’t make perfect! Practice makes progress!” – Wise words by Cami Opresko. Direct 
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